






































































This project contains a detailed valuation of Pfizer Inc. This Equity Research is a 
continuation of the implementation process of a new presentation format for this kind of 
projects, combining the style and rules of ISEG Master Final Project and the CFA institute 
(Pinto, Henry, Robison, and Stowe, 2010) recommendations. 
The choice of Pfizer Inc. comes from my personal interest in the pharmaceutical industry in 
general, and particularly in the capacity of companies in this industry to create value and 
even with very high costs continue to perform extremely well through the years. 
The price target from this valuation was computed using the most adequate method for the 
purpose, the Discounted Cash Flow (DCF) approach, which was complemented with 
Relative Valuation Method approach in order to support the final recommendation.  
Considering the price target obtained was $37.35 representing an upside potential of 15% 
when compared with the price of $32.48 in the end of 2016, the final recommendation is to 
Buy, despite the risks that may occur in the future that can affect the price target. The risk 

























Este projecto contém informaçao detalhada da Pfizer Inc. Este Relatório de Avaliação é 
uma continuação do processo de implementação de um novo formato de apresentação 
para este tipo de projecto, agregando as regras de estilo do Trabalho Final do Programa de 
Mestrado do ISEG e as recomendações do CFA Institute (Pinto, Henry, Robison, and 
Stowe, 2010). 
A escolha da Pfizer Inc. vem do meu interesse pessoal na industria farmacêutica em geral, 
e em particular pela capacidade das empresas desta industria em criar valor e mesmo com 
custos muito altos, continuar a apresentar excelentes indicadores durante todos estes anos. 
O preço alvo desta avaliação foi calculado usando o método mais adequado para o efeito, 
o método dos Fluxos de Caixa Descontados (DCF), que foi complementado com o método 
dos Múltiplos Comparáveis para sustentar a recomendação final. 
Considerando que o preço alvo obtido foi de $37.35, representado um pontencial de 
valorização de 15% quando comparado ao preço da ação no final de 2016, a recomendação 
final é de Compra, apesar dos riscos existentes que podem after o preço alvo. O risco 
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Our final recommendation for Pfizer Inc. stands for Buy, with a price target of $37.35 
and an upside potential of 15%, comparing to the last closing price of 2016. 
The price target was computed using Discounted Cash Flow approach as the 
principal model. We also used Relative Valuation model to support DCF valuation in 
which we reach a price target of $37.66 and an upside potential of 16%. With this price 
target derived from both valuation models it is possible to conclude that Pfizer Inc. is 
currently undervalued.  
Regarding risk assessment, we considered that PFE has a Medium Risk of 
Investment due to the current business challenges the company is facing nowadays.  
The Innovative Health segment is the main driver of company sales, and it is expected 
that it will still account for the major part of revenues in the future. Pfizer Inc. EBIT is 
forecasted to grow in the next five years due to an expected global rise in terms of 
revenues around 6% for companies on this industry, and Pfizer Inc. will still be a big 
player in this industry consequently influenced by this trend. 
From our forecast values, it is expected that Pfizer Inc. profitability will increase in the 
next five years, being possible to say that those years will mark financial recovery. It is 
also expected that the company will still perform very expressive values in terms of 
investments, to increase probability of a potential blockbuster in the pipeline of 
products.  
 
Table 4: Financial Highlights 













Stock Price Price Target Current Price
 2016 2017F 2018F 2019F 2020F 2021F Perp. 
Revenues 52,824 56,152 59,689 63,450 67,447 71,696 74,349 
COGS 12,329 11,679 12,415 13,197 14,028 14,912 15,464 
Op. 
Expenses 
28,489 30,689 32,623 34.678 36,863 39,185 40,635 
EBIT 12,006 13,784 14,652 15,575 16,556 17,599 18,251 







Table 1: Risk Assessment 
Source: AC analysis 
 
LOW MEDIUM HIGH 
 
 
Table 2: Market Profile 
Source: AC analysis 
 
Moody’s Rating A1 
Last Price $32.48 





Table 3: Valuation Output 





Figure 1: Investment Grade 


































PFIZER INC. (PFE) is an American pharmaceutical corporation, dedicated to develop 
and discover medicines, vaccines and healthcare products that can provide advance 
wellness, prevention, treatments and cures that challenge the most feared diseases of 
our time. PFE is listed on NYSE since June 1942, and at the time the first big launch 
was achieved with a product able to treat intestinal worms in the most successful way. 
Thenceforward Pfizer has been applying science and bringing therapies that improved 
and extended human life, becoming one of the largest pharmaceutical companies in 
the world (Figure 2), with headquarters in New York City and with a total average 
number of 96,500 employees (Figure 3). 
The firm currently manages its commercial operations through two different business 
segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). From the 
beginning of 2014 fiscal year until the second quarter of 2016, these operations were 
managed by different business segments, but from now on the firm will manage its 
operations assigning to each segment (IH and EH) the responsibility for their own 
commercial activities and for certain R&D projects. 
The Pfizer Innovative Health (IH) segment is focused on developing and 
commercializing new, value-creating medicines and vaccines that significantly improve 
patients’ lives, as well as products for consumer healthcare. In this segment the key 
therapeutic areas include internal medicine, vaccines, oncology, inflammation & 
immunology, rare diseases and consumer healthcare.  
The Pfizer Essential Health (EH) segment contain legacy brands that already lost or 
will soon lose exclusivity in developed and emerging markets, generic sterile injectable 
products, branded generics, infusion systems and biosimilars. This segment also 
includes R&D organization, as well as contract manufacturing business. 
 
The majority of PFE revenues come from the manufacture and sale of 
biopharmaceutical products. Regarding this, it is important to consider that this industry 
is highly competitive and regulated, resulting in a considerable number of factors and 
challenges that can have a strong impact in the company’s results. The main 
challenges and factors comprise among others: healthcare legislation, the regulatory 
environment, pipeline productivity, the loss or expiration of intellectual property and 
rights, pricing and access pressures and competition and the expiration of co-
promotion and licensing rights, as well as the results of the global economic 
environment. Despite the challenges the industry faces, Pfizer Inc. has been recording 
reasonable values in terms of sales through the years, and that can be expressed by 
the $52.8 Billion recorded in 2016 that represents an approximate 8% growth 
compared to the previous year. In 2016, international revenues represented 50% of 
total revenue (Figure 4). Also in 2016, 55% of total revenue was derived from Pfizer 
Innovative Health (IH), and 45% of the total revenue came from Pfizer Essential Health 
(EH) as can be observed in Figure 5.  
 
Since Pfizer Inc. develops its operations in such a competitive industry sector like the 
pharmaceutical one, the company makes a massive effort fighting the patent 
protection, that once it expires, exposes the specific product from the company pipeline 
that it is intended to protect, and allows competitors to create a biosimilar product which 
plays basically the same role has the one the company created previously. In such a 
situation, generic competition starts and the price of the impacted products drops, 
having a significant adverse effect on PFE revenues. This a normal reality for the 
company that seeks for constant innovation and strives for new potential blockbuster 
products that can offset future losses occurred due to the patent expiration and generic 
competition. 
 
Figure 2: Pfizer Inc. offices 
Source: Company data 
 
 
Notes: Pfizer has office’s spread worldwide. 
 
Figure 3: PFE average 
number of employees 
Source: Thomson Reuters. 
 
Figure 4: Revenues by 
geographic area 





Figure 5: Revenues by 
segment 














































Pfizer Inc. believes that the medicines developed by its teams create significant value 
for patients and healthcare providers, improving treatment of diseases and reducing 
emergency and hospitalization costs. The company is in constant effort looking for the 
best way to work with patients, physicians and payers to prevent and treat diseases 
and improve outcomes. In order to maximize patient access and minimize any adverse 
impact on revenues, the company is still working within the current legal and pricing 
structures, reviewing pricing agreements and contracting methods with payers and 
insurance companies, remaining strictly devoted to the main purpose of innovating and 
bringing therapies to patients that could extend and significantly improve their lives. 
 
Commercial Operations: Pfizer Inc. now manages commercial operations through 
two different segments, Pfizer Innovative Health and Pfizer Essential Health that were 
reorganized officially in the second quarter of 2016. Each segment is composed by 
different products with different features and life stages, forming the firm’s portfolio 
(Table 5 and Table 6). 
The company expects that the Pfizer Innovative Health (IH) portfolio of innovative, 
largely patent-protected, in-line and newly launched products will be sustained by 
constant ongoing investments allowing to develop promising assets and targeted 
business development in areas of focus ensuring a pipeline of very differentiated 
products in the most challenging areas of medical need. The products leaded by Pfizer 
Innovative Health are science-driven, highly-differentiated and require a huge 
engagement with healthcare providers and consumers, while the other segment Pfizer 
Essential Health (EH), aims to generate strong and consistent cash flow, giving access 
to effective, lower-cost, high-value treatments to patients all around the world. It is also 
expected that Pfizer Essential Health (EH) leverages biologic development, regulatory 
and manufacturing expertise to seek and to advance its biosimilar development 
portfolio, and also that leverages capabilities in formulation, development and 
manufacturing expertise to help advancing its generic sterile injectable portfolio. 
  
Research and Development Operations: The Company is still looking to reinforce 
their global R&D organization and is chasing strategies intended to improve innovation 
and overall productivity in R&D, in order to achieve a sustainable pipeline that will 
deliver value in the short and long run. The firm’s primarily research focus is on the 
areas represent in Figure 6, and these R&D priorities include delivering a pipeline of 
highly-differentiated therapies and vaccines with the greatest medical and commercial 
commitment, innovating new capabilities that can lead PFE to a strong leadership in 
the long run, and create new models for biomedical collaboration that will speed up the 
pace of innovation and productivity. Besides the significant internal portion of R&D, the 
firm also seeks for promising chemical and biological lead molecules and innovative 
technologies developed by third parties, to incorporate in internal processes, projects 
and product lines through collaborations, license agreements and alliances with other 
companies, as well as leveraging acquisitions and debt or equity in based investments, 
allowing the company to share risk and cost and access external scientific and 
technology expertise, extremely required to advance their own products as well as in-
licensed or acquired products. 
 
Intellectual Property Rights: As part of the strategy, Pfizer Inc. prospects to continue 
defending aggressively their patent rights whenever appropriate, and will keep 
supporting efforts that impulse worldwide recognition of patent rights. The firm will also 
exert innovative approaches designed to avoid counterfeit pharmaceuticals from 
entering the supply chain and to have better mastery over the distribution of their own 
products, including the generic market whenever their products lose exclusivity. 
Table 5: Leading product by 
segment 
Source: company data 
 
 
Table 6: Leading product by 
segment 
Source: company data 
 
 
Figure 6: R&D principal areas 







Lyrica-US, Japan and other markets





























Negotiation and litigation is part of the strategy in order to pursue valid business 
opportunities, challenging intellectual property rights held by other firms. 
 
Capital Allocation and Expense Management: Part of the strategy of Pfizer Inc. is 
to maintain a strong balance sheet and robust liquidity for the purpose of having the 
financial resources required to take advantage of prudent commercial, business 
development and research opportunities and to directly enhance shareholders value 
by share repurchase and dividends method. Figure 7 represents the chart of dividend 
per share evolution, in which it is possible to see a clear trend of growth over time. 
Considering the existing significant costs related with integrating, acquiring and 
restructuring businesses - and in relation with PFE’s global cost reduction and 
productivity initiatives, that can impact all business and functions including sales, 
marketing, manufacturing, R&D, information technology, shared services and 
corporate operations - Pfizer Inc. also intends to achieve an appropriate cost structure 
for the company; as can be seen in Table 7 the costs associated with acquisitions and 
cost reduction and productivity initiatives have been increasing. 
 
Business Development Initiatives: The firm is strictly committed to advancing its 
pipeline of products and maximize the value of the in-line products through alliances, 
joint ventures, collaborations, equity or debt based investments, dispositions and 
mergers and acquisitions. The company will also continue to pursue a strategic, 
disciplined and financial approach to evaluating opportunities to develop business that 
could be able to generate earnings growth and enhance shareholders value. From 
2014 to the end of 2016, Pfizer Inc. already had sixteen initiatives of this kind that 



























Figure 7: Dividends per share 




Table 7: Cost reduction 
initiatives 
Source: company data, Thousands of US 
Dollars 
 2014 2015 2016 
RESTRUCTURING 
CHARGES 
170 1152 1724 
TRANSATION 
COSTS 
 123 127 
INTEGRATION 
COSTS 
80 219 441 
ASSET 
RESTRUCTURING 
261 122 207 
IMPLEMENTATION 
COSTS 
270 203 340 















The company believes that the optimal Board leadership structure, is composed by an 
independent oversight function of entirely independent directors, providing the 
company with strong operational performance and strengthened necessary to achieve 
the company goals.  
PFE’s has a leadership structure (Figure 8) composed by eleven independent 
directors, one lead independent director, a chairman/CEO and is organized around five 
committees. The committee resume is represented in Table 8. 
 
Audit Committee (1): Consisted by Suzanne Nora Johnson as chair and also by other 
members like Don Cornwell, Joseph Echevarria, Stephen Sanger and James Smith, 
being all members independent, financially literate and qualified as Audit Committee 
Financial Experts. This Committee has the responsibility of overseeing Pfizer’s 
Enterprise Risk Management (ERM) program. This committee works together with the 
Legal Division and the Compliance Division ensuring that ERM is integrated in the 
strategic and operating planning process. It also reviews and receives regular briefings 
regarding Pfizer’s information security and technology risks, including discussions of 
the company’s information security and risk management programs.  
 
Regulatory and Compliance Committee (2): Composed by Frances Fergusson has 
the chair of the committee, and other additional committee independent members, 
namely Don Cornwell, Shantanu Narayen, Helen Hobbs and Suzanne Nora Johnson. 
This committee is responsible for reviewing and overseeing Pfizer’s compliance 
program, evaluating its effectiveness. The committee process information about 
current and emerging risks and regulatory trends that may affect PFE business, 
operations, strategy and performance. The inherent risk are related with health care 
law compliance programs and the status of compliance with applicable laws, internal 
procedures and regulations.  
 
Compensation Committee (3): Composed by James Smith has chair, together with 
other independent members like Don Cornwell, James Kilts and Shantanu Narayen. 
This Committee is responsible for reviewing and approving the company’s overall 
compensation philosophy and oversees the administration of PFE executive 
compensation and benefit programs, policies and practices.  
 
Science and Technology Committee (4): This Committee is composed by the chair 
Helen Hobbs, and other additional independent members: namely, Dennis Ausiello, 
Ronald Blaylock, Don Cornwell, Joseph Echevarria, Frances Fergusson, James Kilts, 
Shatanu Narayen, Suzanne Nora Johnson, Stephen Sanger and James Smith. This 
committee is responsible for periodically examining management’s strategic direction 
and investment in pharmaceutical R&D and technology activities. In addition, this 
committee is responsible to identify emerging issues, assess the performance of R&D 
leaders, and evaluate the sufficiency of the review process by external scientific 
experts. 
 
Corporate Governance Committee (5): This Committee is represented by Stephen 
Sanger, the chair of the committee, and other independent members, namely Ronald 
Blaylock, Joseph Echevarria, Frances Fergusson and Helen Hobbs. The responsibility 
of this committee consists on overseeing the practices, policies and procedures of the 
Board and its committees, advising on the structure Board meeting, recommending 
matter of consideration by the Board, and it also reviews, advises and recommends 
3. Management and Corporate Governance
 
Figure 8: Leadership Structure 





Table 8: Committees resume 
Source: proxy statement for investors 2017 
 
Name (1) (2) (3) (4) (5) 
Ausiello      
Cornwell      
Echevarria      
Fergusson  CHAIR    
Hobbs    CHAIR  
Kilts      
Narayen      
Johnson CHAIR     
Read      
Sanger     CHAIR 
Smtih   CHAIR   
Meetings 14 9 5 4 3 
 




Effective leadership internally and externally
1 Lead independent director
Liaison between CEO and independent directors
11 independent directors





Director compensation, that is approved by the full Board. Also, the committee 
keeps an informed status on company issues related to public policy as well 
as corporate social responsibility, sustainability and philanthropy.  
 
Lead Independent Director: The independent director of Pfizer Inc. 
leadership structure is Dr. Dennis Ausiello, responsible to implement the 
connection between the independent directors of the different committees and 
the CEO of the company, ensuring, following and advising all committees due 
to the high level of scientific expertise and deep understanding of the business 
required for the function. The CEO of the company is Ian Read. Table 6 
summarizes all information stated above. 
 
The company believes that the optimal Board leadership structure, is 
composed by an independent oversight function of entirely independent 
directors, providing the company with strong operational performance and 
strengthened necessary to achieve the company goals. Figure 9 shows the 
current leadership structure of Pfizer Inc. 
 
This corporate governance structure, in which Mr. Read is the CEO and the 
chairman provides Pfizer Inc. a unified structure with strong consistent 
leadership. Having one clear leader in both roles, with deep industry expertise 
and company knowledge, provides decisive and effective leadership internally 
and externally, which is a reasonable strength for the company. Having all the 
independent directors providing substantial oversight on CEO’s performance, 
allows the directors to evaluate the effectiveness of its leadership structure 
and act in function of the company and shareholders best interest. 
 
Social Responsibility: 
In relation to social responsibility, Pfizer Inc. believes that everyone should 
have access to quality healthcare and healthy lives. The company combines 
different methods and approaches involving the company’s people, products 
and funding along with partnerships with governments, nonprofit organizations 
and foundations that can impact on public-health systems facilitating access 
to healthcare for under-served communities, which is a purpose the company 
wants to reach. The current portfolio of programs range from donating their 
own medicines, volunteering employee skills to providing grants and 
investments that support social entrepreneurs and enterprises, promoting 
healthcare delivery and local innovation. With their portfolio of programs, the 
company aims to impact and achieve the following goals: Building 
Healthcare Capacity, Expanding Access to Medicines, Promoting 
Corporate Citizenship.  
 
Shareholder structure: 
The Shareholder structure at 31/12/2016 had a share capital of 5,955,125,843 
shares outstanding with a free float of 0.04%. Respecting the shareholder 
structure, on Figure 10, the majority of the shares are held by institutional 
investors (mainly composed by investment managers like hedge funds, 
insurance companies, venture capital, pension funds, private equity and other 
corporations) that own 71.35% of the shares, and by private investors that own 
28.61% of the shares. The management team of PFE, owns less than 1% of 
the total shares issued by the frim. Pfizer Inc. shares are mostly held by North 
American investors with 85% of the shares, followed by Europe with 13% of 
the shares (Figure 11). Table 9 provides information on the top three investors 
with more than five percent participation of PFE common stock. 
Figure 10: Types of 
shareholders 
Source: Thomson Reuters 
 
 
Figure 11: Share Holder 
Nationality 





Table 9: Top Investors 
Source: proxy statement for investors 2017 
 
Name 




























Global Economic Outlook: 
According to IMF (Figure 12), the global economic outlook is favorable. From 2014 
to 2016 there was a decrease in terms of global GDP growth (-8.83%), as a result of 
the political and financial crisis faced worldwide, meaning a drop of around 0.3% on 
global growth. For the coming years, the IMF forecasts that the world GDP is going to 
grow between 3.4% and 3.8%. 
In what concerns advanced economies, it was registered also on these economies a 
drop on GDP (-15.8%) between 2014 and 2015, due to the impacts of negative inflation 
and large debts over several countries, but it is foreseen that the GDP growth rate on 
these countries fluctuates around 1.6% and 1.8% in the following years as Figure 13 
suggests.  
Emerging markets and developing economies, had a negative growth from 2014 to 
2015 due to the recession some countries in Latin America faced at the time, along 
with a slowdown in terms of growth registered in some countries of Asia. However, it 
is expected by the IMF that the growth rate in the following years improves 
substantially, as already happened from 2015 to 2016 (Figure 13). 
 
China Economic Outlook: 
China is an important player for Pfizer Inc., due to the fact that the company is the 
biggest biopharmaceutical company in China, already launched 50 innovative drugs in 
the country until today, and has two R&D centers in China with over 10,000 employees, 
spread over 300 cities. 
Figure 14 represents China’s GDP growth, in which it is possible to see a clear trend 
of decrease for the coming years, and according to the IMF it is expected that the 
growth rate continues do decay slowly over time. Since China’s GDP growth is slowing 
down, it is foreseen that in the near future China’s economy will be attracting less 
investment, and higher costs of borrowing. On the other hand, the chart line in Figure 
14, shows an increasing tendency for inflation over time forecasted by the IMF for the 
following years. In what respects to China’s economic outlook, it may present 
moderate risk to PFE. 
 
United States Economic Outlook:  
United States has a very important role in Pfizer Inc. activity, considering that is the 
company’s headquarters and around 50% of revenues came from this country. The 
policies created in this country and its economic performance are relevant to analyze 
future outcomes, since the United States is a big driver of the company’s activity.  
In what concerns GDP growth and inflation (Figure 15), it is possible to see a significant 
decrease in terms of GDP from 2015 to 2016, slowing down around 38.5% that was 
motivated by strong consumption and firm labor market counterbalanced by the 
weakness in nonresidential investment, dollar appreciation, financial turbulence earlier 
in the year, and big policy uncertainty related to electoral cycle that contributed to a 
swing on the headline growth number of GDP. However, the IMF forecast that the GDP 
growth will improve in the following years. 
The inflation rate registered a very low value in 2015 (0.1%), but it increased quickly in 
the following year, since the United States’ Federal Reserve managed to decrease 
interest rates in order to target an inflation rate at 2%, a level high enough to encourage 
a healthy level of consumer spending and also protecting from risks of deflation that 
could lead the economy to slowing down. The IMF forecasts that the inflation in coming 
years will continue to increase until 2017, and fluctuate around 2.4% over time. The 
United States outlook seems favorable for Pfizer Inc. 
4. Industry Overview 
Figure 12: Global GDP growth 
Source: International Monetary Fund, Growth in 
Percentage 
 
Figure 13: Advanced and 
Developing Economies GDP 
growth 
Source: International Monetary Fund, Growth in 
Percentage 
 
Figure 14: China GDP growth 
and inflation 





Figure 15: US GDP growth and 
inflation 














































Pharmaceutical Industry Overview: 
The pharmaceutical industry is composed by companies engaged in researching, 
developing, manufacturing and distributing drugs for human and veterinary use. The 
new medicines discovered by those companies have a huge impact on global health, 
prosperity and economic productivity by saving lives, increasing life spans, preventing 
surgery, diminishing pain suffering, and shortening hospital patients list. Advances in 
medicines have eliminated deadly diseases and help controlling life-threatening 
conditions. The innovative medicines developed by those companies are chemically 
derived and are developed through extensive R&D and clinical trials. These innovating 
products rely on patents, regulatory data protection and other forms of intellectual 
property rights (IPR) to justify the investment needed to bring products to the market. 
In the United States the patent term is 20 years, and medicines are eligible to have at 
least 5 years of market exclusivity depending on the time between patent validity and 
U.S. Food and Drug Administration (FDA) approval. This industry is highly dependent 
on the development of new molecules to replace revenue stream of older drugs that 
are approaching the expiration of their patent terms, and the pricing of the new 
products is designed to cover future and past expenditures on R&D. In the United 
States, upon patent expiration, a manufacturer can produce a generic medicine that is 
basically a copy of the innovative pharmaceuticals containing the same active 
ingredients and are identical in what concerns to strength, dosage and form of 
administration.  
In the United States the pharmaceutical industry represents the largest share in terms 
of R&D business, accounting for approximately 17% of all R&D spending in the U.S. 
which means this industry invests 12 times more in R&D per employee and has the 
highest growth rate (CAGR of 2.8%) in R&D investments across all manufacturing 
industries (Figure 16). The investments in this industry not only bring new medicines 
for patients but they also give strength to the U.S. economy, since they create high-
quality and high-wage R&D and manufacturing jobs all over the country, creating 
around 4.5 million direct, indirect and induced jobs (Figure 17). 
 
Regulatory environment: 
The loss or expiration of intellectual property rights and the expiration of co-promotion 
and licensing rights can have a notable unfavorable effect on the industry. Each 
company of the industry has a portfolio of branded products with multiple patents 
expiring at different dates. Once patent protection has expired, companies lose 
exclusivity on their products, and generic pharmaceutical manufacturers are able to 
produce identical products and sell them afterwards for a lower price. Each company 
of this industry is particularly affected by this issue, with Figure 18 representing the 
worldwide sales at risk from patent expiration and the respective forecast for the 
following years. 
The process of launching a product represented in Table 10 is regulated by the U.S. 
Food and Drug Administration (FDA), having a special role in approving to test the 
new medicine in humans. 
As part of the pharmaceutical industry, Pfizer Inc. revenues and product approval are 
dependent on the FDA, being the company along with all competitors reliant on the 
parameters imposed by the regulator, this representing a lower risk for the company, 
because of the previous knowledge of the standards FDA is ruled by. 
 
Table 10: Pharmaceutical industry value chain 








Figure 16: Industry R&D 
spending 
Source: Evaluate Pharma World preview 2016, 
Millions of US Dollars. 
 
Figure 17: Industry Job Creation 




Figure 18: Worldwide sales at 
risk  
Source: Evaluate Pharma World Preview 2016, 
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1,882,000 Induced Jobs

















Demand and Supply:  
The consumption of medicines is represented in Figure 19, in which it is possible to 
identify a growing trend from 2014 to 2016, and a forecasted growth rate of 6.2% for 
the coming years until 2021. The demand for medicines is measured by its medical 
prescription, and is influenced by demographic and economic trends, including a 
rapidly aging world population and an associated rise in chronic diseases, increased 
urbanization and higher disposable incomes, greater government expenditures on 
healthcare and growing demand for more effective treatments.  
The actual world population is currently growing, being nowadays 7.5 billion. As it 
grows, populations also becomes older and more sedentary. If previous trends are 
held constant many of those people will necessarily have health problems in the future. 
Figure 20 helps supporting the idea that currently Europe’s and North America’s 
population is getting older, which increases the use of specific drug therapies, but it 
also suggests that actual population structure in emerging economies like Asia, Latin 
America and Africa, make companies want to shift towards those economies, where 
pharmaceutical sales are forecasted to expand at higher rates. Further reforms of 
legislative systems, especially regarding patent protection and enforcement, as well as 
improving regulatory conditions, make these markets increasingly attractive for 
companies of the pharmaceutical industry, in spite of the immensity of challenges of 
political, cultural, social and religious order. Despite the fact there is real uncertainty 
across all matters lived on those emerging economies, in 2016 the global 
pharmaceutical industry generated around 30% of its total sales in emerging markets 
(Figure 21), a growing trend percentage through the last 10 years. 
 
Another driver of consumption of medical therapies developed by the pharmaceutical 
industry is the increasing number of chronic diseases, which are generally an incurable 
illness or condition, such as heart disease, asthma, cancer and diabetes. In the United 
States the prevalence of chronic diseases, complications and risk factors climbed over 
the years and are forecasted to climb even more in the following years (Figure 22). 
Actually, around 47.7% of the population in the U.S., or 149 million residents, are living 
with one or more chronic conditions, and the number of people with chronic diseases 
and risk factors along with the aging factor combined, are forecasted to continue up 
swinging in the next years, which will drive up the total demand for medicines produced 
by the pharmaceutical industry. In addition, there is an increasing trend on world 
healthcare expending by governments, the U.S. being the world leader of expenses in 
percentage of GDP. In the United States the healthcare expenses are projected to 
grow at an average rate of 5.8% from 2015 to 2025, reaching in 2016 for the first time 
$10,000 per capita spending, which will definitely contribute for the seeking of new 
medicines and therapies and rising consumption of the new developed therapies 
produced by the pharmaceutical industry. The current consumption of medicines 
present a favorable outlook for Pfizer Inc. 
 
The supply of medicines is influenced by exchange rates affecting companies’ 
profitability, and sales whether they made marketing and pricing adjustments in order 
to control for potential losses. The dollar increase has been a reality (Table 11), the 
valuation of this currency has been so quick that major companies struggle to adjust. 
U.S. companies in the pharmaceutical industry are finding to their products becoming 
more expensive to foreign buyers, which might slow the sales rate and strain export 
negotiations, making companies face difficult decisions on pricing and market strategy. 
In Table 11, it is possible to see that the U.S. Dollar currency index, which indicates 
the general international value of the dollar computing the average of the exchange 
rates between U.S. Dollar and other world currencies, has been growing. The forecast 
made by Bloomberg Composite indicates that the currency will depreciate from 2016 
to 2019, due to the monetary policies indicating an increase in Fed Funds Rate in the 
following years. The exchange rate represents a moderate risk for Pfizer Inc. 
Figure 19: Worldwide total 
prescription of drug sales 
Source: Evaluate Pharma World Preview 2016, 
Millions. 
 





Figure 21: Pharma market sales 
Source: PWC, Pharma emerging markets 
 
Figure 22: People with Chronic 
Disease 
Source: Public Health: Chronic Disease Driver 
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Table 11: U.S. Dollar Currency Index 
Source: Bloomberg.  
 
 
The price of medicines has been under discussion for many years, and pharmaceutical 
companies know very well that a new medicine development takes an average 12 
years to develop from the initial discovery stage to reach the market and consumers, 
and the costs of developing those drugs are enormous with a very small percentage 
of the prototypes reaching the market. The risk involved in developing a new successful 
therapy is huge. Considering the substantial amounts of spending’s in R&D that makes 
it a resource intensive process, the challenge for this industry is to balance prices in a 
way that of diminishes the actual tension of those companies in keeping shareholders 
happy and keeping the world happy as well. Figure 23 represents the world spending 
on medicines in billions of U.S. dollars, which indicates a clear trend over past years 
on world spending in medicines and a forecast of increasing expenditures on this 
matter in 2021.  
The mature markets of this industry have evolved economically, demographically and 
structurally and pharmaceutical companies continued to pursue their old business 
model of higher prices for new features of their medicines, even if they deliver very 
little extra value. But nowadays consumers seek for more value in the medicines they 
buy, and paying the same money or less than before. However, the dilemma is that 
many of those medicines in the companies’ pipeline were developed before those 
market forces were that strong and some products may be unable to meet consumers’ 
expectations. The price politics represent a medium risk for Pfizer Inc. 
 
Debt and Financing: 
Pfizer Inc. has a strong financial position considering the complex environment where 
it operates. The company has significant operating cash flows, access to capital 
markets, financial assets, and ready to use lines of credit and rotational credit 
agreements, that allows the firm to predict that it will maintain the ability to meet the 
liquidity required for a prosperous future. The long-term debt is rated with high quality 
investment grade by both S&P and Moody’s (Table 12). Due to the continuously 
environment changing environment the company is still planning to adopt a 
conservative approach to financial investments made. The two major corporate debt-
rating organizations, S&P and Moody’s, attribute ratings to the company short term 
and long term debt. A security rating is not a recommendation to buy, hold or sell 
securities and the rating is liable to revision or withhold at any time by the rating 
organization. Table 12, provides the current ratings assigned by these rating agencies 
to the company’s commercial paper and senior unsecured long-term debt. The full list 
of PFE bonds and maturities is represented in Table 13. 
In terms of financing, the net cash used by Pfizer Inc. in financial activities was $8.9 
billion in 2016, which decreased when comparing with the $10.4 billion in 2015. This 
decrease in net cash observed in 2016 occurred because of the issuance of long-term 
debt in $11 billion and purchases of common stock of $5 billion, partially offset by net 
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Figure 23: World spending on 
medicines 
Source: IMS Health, Millions of US Dollars 
 
Table 12: Pfizer Inc. Rating 









Moody’s P-1 A1 Stable 
S&P A-1+ AA Stable 
 
Table 13: PFE senior unsecured 
long-term debt 




4.55% May 2017 - 
1.1% May 2017 - 
1.2% June 2018 1250 
1.5% June 2018 1000 
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5.75% June 2021 2108 
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7.2% March 2039 2500 



























of $7.7 billion, higher cash dividends paid of $7.3 billion and lower proceeds from the 
exercise of stock options of $1 billion. The environment surrounding Pfizer Inc. in terms 
of its debt and financing represents a moderate risk for Pfizer Inc. 
 
The Industry is changing: Meanwhile, the innovative pharmaceutical industry is 
currently facing unprecedented challenges caused by slower growth of sales, expiring 
patents, increasing competition, shorter lifecycle of products, tighter regulations, 
adverse media coverage and reputational damage, and a decline in the number of new 
innovative medicines under development. There was a concern in the industry that 
even though the increasing enormous amounts expended on R&D, the industry is 
producing far fewer new drugs and effective therapies than it did decades ago, but in 
order to fight that trend the companies of the industry are doing considerable efforts to 
adjust to a more competitive environment, doing so by shifting manufacturing and other 
operations overseas, updating research pipelines, reducing employment and 
organizing mergers and acquisitions seeking out for new deals that could generate the 
revenues investors expect.  
 
Peer Group Analysis:  
This point will stand out when analyzing Multiples Approach (Relative Valuation), 
since it is crucial for investors to compare the performance of similar companies. In 
Pfizer Inc.’s case, it is important to notice that the company has many competitors in 
its business activity. Table 14 identifies the main competitors of Pfizer Inc. ranked by 
Net Sales volume in 2016, in which PFE was only outperform by Johnson & Johnson. 
All the companies in Table 14 are U.S. based. As Figure 24 and Table 15 suggests 
currently Pfizer Inc. has around 14% of market share in terms of net sales, which 
makes it one of the biggest players in the pharmaceutical industry. The peer group 
comparison is based on major pharmaceutical companies of comparable size (Table 
16). 
 
Table 16: Pfizer Inc. Peer Group 
Source: AC analysis 
 




Price/Earnings Net Income 
($M) 
PFE Pfizer Inc. 33.86 201,641 28.94 7,215 
BMY Brystol-Myers 
Squibb 
55.67 91,717 19.33 4,836 
LLY Eli Lilly 81,33 89,736 39.29 2,186 
AGN Allergan 243.05 85,964 NM 14,973 
AZN AstraZeneca 30.86 78,113 22.20 3,499 
NVO Novo Nordisk 38.78 76,108 18.21 5,382 
JNJ Johnson & 
Johnson 
123.74 335,446 20.80 16,505 
NVS Novartis 77.06 202,445 27.52 6,712 
GSK GlaxoSmithKline 40.78 197,872 88.65 1,125 
MRK Merck 62.58 171,565 45.02 3,920 
SNY Sanofi 46.91 121,218 26.06 4,968 
 
From a multiples perspective it is easy to find a truly comparable peer group due to the 
fact that there are many U.S. players with the same comparable regulation and the 
same core business, even if they produce different products. The process of peer 
group selection is explained in appendix I. 
 
 
Table 14: Pfizer Inc. Peer Group 
Source: AC analysis 
Ticker Company Name Net 
Sales 
($M) 
JNJ Johnson & Johnson 72,714 
PFE Pfizer Inc. 52,824 
NVS Novartis AG 48,518 
MRK Merck & Co 39,807 
SNY Sanofi 36,623 
GSK GlaxoSmithKline  34,897 
AZN AstraZeneca 24,633 
LLY Lilly 21,585 
BMY Bristol-Myers Squibb 19,965 
NVO Novo Nordisk 15,863 
AGN Allergan 14,570 
 






Table 15: Peer group market 
share 
Source: AC analysis 
Ticker Company Name Share 
JNJ Johnson & Johnson 19.04% 
PFE Pfizer Inc. 13.83% 
NVS Novartis 12.70% 
MRK Merck 10.42% 
SNY Sanofi 9.59% 
GSK GlaxoSmithKline 9.14% 
AZN AstraZeneca 6.45% 
LLY Eli Lilly 5.65% 
BMY Brystol-Myers 5.23% 
NVO Novo Nordisk 4.15% 



















In order to have an idea of Pfizer Inc. current position in the market, it is important to 
build a SWOT analysis for PFE’s competitive position. 
 
Table 17: SWOT analysis of PFE 
Source: AC analysis 
 
Strengths Weakness 
 One of the market leaders in the 
industry. 
 Diversified portfolio of products. 
 R&D focused. 
 M&A increase good reputation. 
 Strong brand name. 
 Cash available to pay dividend and to 
service its debt. 
 
 Strong competition of similar products 
in the market. 
 High risk when spending R&D 
 Healthcare fraud involvement 
 
Opportunities Threats 
 Emerging markets demand. 
 Expansion of biologic pharmaceutical 
market. 
 Emerging companies in the sector 
can increase M&A deals. 
 Strategic partnerships. 
 Enter in generic markets with its own 
off-patent medicines. 
 Increasing healthcare awareness. 
 Government Regulation 
 Economic slowdown 
 Increasing competitors 
 Next generation medicines 
 Patent expiration 
 
Overall, Pfizer Inc. strengths and opportunities are foreseen to overcome its 
weaknesses and threats in the future.  
 
Porter five forces analysis (Figure 25): 
Threat of new entrants (LOW): 
There are several barriers to enter the market due to the huge costs associated with 
R&D for new medicines development. The costs associated with R&D are intense for 
new entrants into the pharmaceutical industry. Also capital requirements necessary in 
this industry to invest in new technology, machinery, and raw materials are constant 
and massive. Another issue for new entrants is the path of loyalty between the 
company and the customer that is already achieved by big the big companies in the 
industry. Another difficult issue for new entrants is the government policy regulation 
(FDA), which restricts the pharmaceutical industry in a way that potential new entrants 
can see their investments defeated by the tight regulation imposed in matter of 
efficiency in clinical trials. 
 
Rivalry (HIGH): 
Rivalry among competitors is high due to the already established companies in the 
sector along with the exit barriers and product differentiation. The large number of 
companies in the sector means that they have to compete for the same customers, 
resources and market leadership, which causes companies to go around patent issues 
and develop similar medicines that could treat the same health condition. The high 
costs related to exit barriers means that it’s expensive to get rid of a product, service 
Figure 25: Porter´s five forces. 























or subsidiary, forcing companies to put in all efforts necessary and fight for their space 
in the market. This high rivalry makes companies spend a large portion of their budgets 
on product differentiation marketing among competitors. 
 
Bargaining power of suppliers (LOW): 
Prior to the expiration of a patent, the cost of producing a blockbuster is lower when 
compared to the potential value of sales when the medicine reaches the market. When 
a generic medicine comes to the market, there are still many suppliers to choose from, 
the resources required to produce medicines are not restricted to a limited set of 
suppliers. But generally speaking, pharmaceutical companies owe those suppliers for 
their own security, integration and quality control, and when this is not the case, 
individual scientists usually sign away the intellectual rights to any discovered product 
while working for the company, leaving them with very low bargaining power. However, 
if an independent group of scientists makes a discovery, that company or institution 
which they are part of, can have a large bargaining power, but usually when it happens 
the two institution merge.  
 
Bargaining power of buyers (MEDIUM): 
The normal individuals that consume medicines not making part of any specific union 
or group, consist a low bargaining power, as well as the pharmacies that sell especially 
what doctors recommend. However, health care insurance agencies, hospitals and 
HMO’s and government can have significant bargaining power because they can 
choose to not subsidize certain medicines or unbalance the subsidies between 
medicines. 
 
Closeness to substitute products (HIGH): 
When a medicine is in its period of exclusivity not many substitutes exist, but once the 
period of exclusivity ends, there are a variety of substitutes like generic medicines. 























With a price target of $37.35 and an upside potential of 15% comparing to the price 
at the end of 2016, using the Discounted Cash Flow method (Table 19), and Low 
Risk assessment, our recommendation stands for Buy (Table 18). Besides the 
Discounted Cash Flow (DCF) method the Multiples Valuation Approach (Table 20) 
also supports our view with an average price target of $37.66 and an upside potential 
of 16%.  
 
Pfizer Inc. was evaluated as a consolidated group under those two different valuation 
methods, in which is contemplated the two main segments of the company business 
are complemented, the Innovative Health and Essential Health segments. Pfizer Inc. 
is a company focused on delivering high quality products, that could create significant 
value for patients and healthcare providers, and assessing that main objective and 
considering the company’s current structure, it is predictable that the company would 
still develop and commercialize new medicines and vaccines through the Innovative 
Health segment accounting for 55% of the total Revenue in the future, while legacy 
brands that already lost or will soon lose market exclusivity will still be in charge of  the 
Essential Health segment accounting for 45% of total Revenue in the Future.  
 
For the foreseen period, we predict that Earnings per Share (EPS) will still increase 
due to the existing growth trend in the industry and also due to the typical feature of 
mergers and acquisitions of the industry that allows the acquirer to keep feeding its 
pipeline with outstanding products and at the same time guarantee a good level of 
return for company shareholders, lined up with company strategy. In 2016 the 
company registered values in a growing trend of $1.18 in terms of EPS, and 
consequently on dividends per share of $0.32. The possible existence of a merger or 
acquisition with another company of the industry is almost a certainty, but it’s virtually 
impossible to predict who is going to be acquired or when or how. 
Pfizer Inc. was characterized by a relative stable stock performance in 2016, with 
stock price achieving a minimum of $29.04 on March 6th, 2016 and a maximum of 




In this particular industry there are some investment risks that cannot be controlled 
by management like economic, market and operational risks, as well as the current 
price of medicines. The global economic slowdown from several countries affects 
directly the companies in the industry and the impact of pressure on prices induces a 
truly innovative medicine with proven improvements in safety and efficacy to still 
demand for premium prices and secure and excellent return on investment, but as the 
breakthrough products are not so easy to be approved and commercialized, the 
companies in this industry are in constant focus on cost cutting opportunities.  
 
Besides those risks, it is important to understand that companies like Pfizer Inc. spend 
very expressive amounts of capital in R&D processes in order to develop their new 
products, which can take an average 12 years to fulfill all the criteria to be 
commercialized. The approval of a new medicine is under the supervision of the FDA, 
the regulatory entity. Those are the main investment risks surrounding the company’s 
environment and the ones investors should be aware of.  
Moreover, several sensitivity analysis were performed to assess the impact of 
changing variables that might affect DCF valuation, along with a deeper analysis of 
PFE’s main risks identified in the Investment Risks section. 
5. Investment Summary 
 
Table 18: Investment Grade and 
Risk classification matrix. 
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Table 19: Discounted Cash Flow 
Valuation. 
Source: AC analysis 
EQUITY VALUE 222,707 










Table 20: Multiples Valuation 
Approach. 






















Pfizer Inc.’s financial statements, Balance Sheet and Profit and Losses statement 
(P&L), for historical and forecast period are available in Appendix A and Appendix B 
respectively. 
 
As stated before, the two different methods to evaluate PFE were an absolute valuation 
method and a relative valuation method. Concerning the absolute method valuation 
model, we used the Discounted Cash Flow (DCF) approach. With the amount of 
information available, this method was the most appropriate to reach an enterprise 
value for the company, which was computed using Free Cash Flow to the Firm 
(FCFF) of Pfizer Inc. as a group.  
 
For the relative valuation model, the Market Multiples approach was implemented. To 
achieve a price target, a Peer group was selected from all competitors. The selected 
companies had to obey to a certain number of criteria in such a way that it could be 
possible to make them comparable companies in terms of risk, dimension and 
structure. In this valuation method we used several multiples in our analysis such as 
Enterprise Value to EBTIDA, Enterprise value to EBIT, Enterprise Value to Sales, P/B 
and P/E. A more detailed look into those multiples can be seen in Appendix I. 
 
Forecast Analysis: 
The Total Revenue of Pfizer Inc. accounts for $52,824 M in 2016, which consists 
basically in sales and services from the two existent segments: Innovative Health and 
Essential Health.  
The global sales of medicines are forecasted to rise at a compound annual rate of 
6.3% over the next 5 years according to Evaluate Pharma World Preview 2016, 
Outlook to 2022 report from the life science market intelligence firm. Also, the IMS 
forecasts a rise on sales around 6% according to IMS’s Outlook for Global Medicines 
through 2021 report. The actual growth rate forecasted for this industry (Figure 26) is 
slightly slower than in the previous five years, which were characterized by patent cliff 
along with the global attention on Hepatitis C cure. We believe that this is the most 
likely scenario due to the combination of increasingly vocal politicians railing against 
United States medicines pricing, a weak global economy recovery, uncertainty created 
by Brexit and the United States presidential race, that have all contributed to a collapse 
in the forecasted growth rate for this industry. This 6.3% global growth is a blend of 
different growth rates in different regions and countries, which contribute to this final 
value’s accuracy. Table 21 provides a summary of the forecasted growth rates for 
different countries.  
The United States is leading the global market, being expected to growth around 6% 
in the next five years. China has been losing its pace in terms of growth, registering 
growth rates above 10% in the past, and now it is forecasted to have a more modest 
growth rate for the five coming years of around 5.6%. The developed markets like U.S., 
Japan, Germany, U.K., Italy, France, Spain, Canada, South Korea and Australia have 
gradually slid down in terms of growth as emerging countries markets have risen. The 
developed markets are forecasted to grow around 5.5%. 
Global Revenue growth will be driven by different patterns over the next five years with 
developed countries balancing a substantial surge of growth focused on cost control, 
pricing, transparency, and outstanding innovative products across countries, while 
emerging markets are expected to grow slowly due to the widely varying economic, 
social and healthcare environment (Figure 27).  
Moreover, we believe that after 5 years the industry will be more stabilized and 
predictable with a growth rate following the Real World GDP growth rate of 2.25%. 
6. Valuation 
 
Figure 26: PFE Total Revenue 
Forecast 
Source: AC Analysis 
 
 
Table 21: Growth Forecast by 
Region 













Figure 27: World consumption 































































Cost of Goods and Services 
In the last three years Pfizer Inc. accounted its Cost of Goods and Services as an 
average of 20.80% of total Revenue. This is an important measure that is influenced 
by the cost of global operations of the company’s products, loss of exclusivity, 
acquisitions measured at fair value, foreign exchange rate, and costs incurred to 
implement the cost reduction initiatives. In the future, we believe that future costs of 
goods and services will increase as the total amount of revenues also increase, 
generating a future output in terms of gross margin as Figure 28 represents. This cost 
includes cost of finished goods, work in process and raw materials. 
 
Operating Expenses 
Operating Expenses consist in the sum of values related to Selling, Informational and 
Administrative Expenses (including internal and external costs of marketing, 
advertising, shipping and handling), Research and Development (costs of proprietary 
R&F efforts, and costs related to licensing agreements), Depreciation and Amortization 
(Property, Plant and Equipment, intangible assets and Goodwill) and Other Operating 
Expenses. In 2016 operating expenses registered a value of $28,489M, which 
represents 54% of revenues in that year. Considering the last three years, we believe 
that Operating expenses will register 54.65% of total revenues for the foreseen years. 
The heavy weight on this operating expenses is the cost related to Selling, 
Informational and Administrative Expenses that represents a flat percentage of 
revenues over years around 28%. Figure 29 represents the forecasted weight of each 
operating expense in total operating expenses, for the future. 
 
Debt 
Currently the company has a high level of net debt accounting for $24,236. Observing 
Table 22 and having in mind the company’s strategy of maintaining credit rating high, 
we anticipate that the level of net debt might decrease over the next years and 
becoming more stable afterwards. We consider that Net Debt was computed by 
summing long term and short term debt, minus cash & cash equivalents and short term 
investments together. To forecast future values of net debt we used the assumptions 
made for each of these parameters. Having this in mind we assumed that the target 
capital structure in terms of debt for the company from 2016 to 2022 period would be 
15.7% for debt and 84.3% for equity.  
 
Capital Expenditures (CapEx) 
Pfizer Inc. strategy in terms of capital expenditures takes into account the company’s 
financial sustainability, maximizing its optimization investing in the improvement of their 
infrastructures that allows the company to keep feeding the pipeline with potential 
outstanding products. Regarding the historical values of Cash Flow Statement for 
capital expenditures, it is possible to notice that the amounts expressed are very stable 
and constant, and so we considered that this firm is already used to expend regular 
amounts of capital for this purpose. For the forecasted years we assume that CapEx 
will record very similar values to those registered in the previous years.  
 
Depreciation & Amortization (D&A) 
Observing Depreciation and Amortization available on the Cash Flow Statement of the 
company it is evident that Depreciation & Amortization registered very flat values in the 
previous years. Considering this, we believe that in the future the amounts related to 
Depreciation & Amortization will follow the same constant trend like it did in the past. 
 
Figure 28: PFE Costs of Goods 
& Services 
Source: AC Analysis, Millions of US Dollars 
 
 
Figure 29: Operating Expenses 
Source: AC Analysis 
 
Table 22: Net Debt Forecast 
Source: AC Analysis, Millions of US Dollars 
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Net Working Capital (NWC)  
The Changes in non-cash working capital were computed by summing the 
forecasted values in each year correspondent for changes in Accounts Receivable, 
Changes in Inventories, Changes in Accounts Payable and Increase or Decrease in 
other Operational Assets or Liabilities. Doing those computations it was possible to 
deduct the net working capital forecasted for the next years. The forecasted values 
that compose NWC were obtained using the assumptions related to the Cash Flow 
Statement. More detailed information can be seen in Appendix L. 
 
Discounted Cash Flow:  
The result of Discounted Cash Flow Valuation was a price target of $37.35 for the 
end of 2016 (Table 23), which means that Pfizer Inc. has an upside potential of 
15%. In this valuation methodology PFE is currently undervalued, which leads our 
recommendation under this method for Buy. More detailed information about the 
procedures and computation of DCF are available in Appendix H. 
 
As previously mentioned the Discounted Cash Flow valuation was computed 
considering Pfizer Inc. as a group following two major steps: calculate annual FCFF 
and the weighted average cost of capital, WACC. The FCFF provides an analysis of 
the future cash flow available for Pfizer Inc. capital suppliers after all operating 
expenses, while WACC provides an analysis of the required rate of return of PFE 
capital suppliers and the capital structure in the forecast period. 
 
The EBIT is an important step to derive the FCFF, consisting in subtracting Cost of 
Goods and Services and all Operating Expenses from Total Revenues (Table 24). 
Its computation for the last three years and for the forecasted period are summarized 
in Table 25:  
 
Table 25: EBIT Forecast 
Source: AC Analysis, Millions of US Dollars 
 
We forecast Future Cash Flows of Pfizer Inc. to grow until the end of the valuation 
period using the following definition to computing FCFF: 
 
𝐅𝐂𝐅𝐅 = 𝐄𝐁𝐈𝐓 ∗ (𝟏 − 𝐌𝐚𝐫𝐠𝐢𝐧𝐚𝐥 𝐓𝐚𝐱 𝐑𝐚𝐭𝐞) + 𝐃&𝐀 − 𝐍𝐞𝐭 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐢𝐧 𝐖𝐂 − 𝐂𝐚𝐩𝐄𝐱 
 







 2016 2017F 2018F 2019F 2020F 2021F Perp. 
Revenues 52,824 56,152 59,689 63,450 67,447 71,696 74,349 
COGS 12,329 11,679 12,415 13,197 14,028 14,912 15,464 
Op. 
Expenses 
28,489 30,689 32,623 34.678 36,863 39,185 40,635 
EBIT 12,006 13,784 14,652 15,575 16,556 17,599 18,251 
 
Table 23: DCF Output 
Source: AC Analysis 
 
Enterprise Value 237,487 
Net Debt 14,780 M 




Price Target $37.35 
Current Price $32.48 
 
 
Table 24: EBIT assumptions 
Source: AC Analysis 
Revenues 
Less: Cost of Goods and Services 
Less: Selling, General & Admin. 
Less: R&D expenses 
Less: D&A 
Less: Other Operating Expenses 








Table 26: FCFF Forecast 
Source: AC Analysis, Millions of US Dollars. 
 
DCF Assumptions:  
The valuation period considered in our work was 5 years, from 31 December 2016 
to 31 December 2021. After this time period, the terminal value is added. 
 
The Discount Rate applied to the future cash flows is derived from the actual 
Weighted Average Cost of Capital (WACC). To compute the WACC rate for our 
analysis we used the following expression (Table 27):  
 
𝐖𝐀𝐂𝐂 =  𝑲𝒆 ∗ [
𝑬
𝑬 + 𝑫
] + 𝑲𝒅 ∗ [
𝑫
𝑬 + 𝑫
] ∗ (𝟏 − 𝒕) 
 
In WACC calculation and assumptions, we considered a more reliable and detailed 
analysis to compute the Levered Beta, using first the Unlevered Beta from Aswath 
Damodaran’s database and Modigliani-Miller analysis, to take into account PFE’s 
target capital structure. Using the value of Unlevered Beta for industry we were able 
to compute a Levered Beta of 1.04 using the following expression: 
 
𝛃𝐥 =  𝛃𝐮 ∗ [𝟏 +
𝐃
𝐄
(𝟏 − 𝐭)] 
 
Using the Levered Beta it was possible now to derive the Cost of Equity (Ke) for 
the company, under the Capital Asset Price Model (CAPM). A specific adjustment 
factor was used to account for certain operational risks existent in emerging 
countries (in the spirit of Godfrey and Espinoza, 1996), which we called “alpha” to 
simplify (Table 28). Then, the Cost of Equity represents the rate of return that 
stakeholders require for the company. Our computations show a cost of equity of 
10.29%, which was computed using the following formula: 
 
𝐊𝐞 =  𝐑𝐟 + 𝛃𝐞 ∗ 𝐄𝐑𝐏 +  𝛂 
 
 In what concerns the Risk Free Rate (Rf), we used the 10 years United States 
Treasury Bond, which is perceived as a safe investment and coincides with the fact 
the company is U.S. based. We used as risk free rate a value of 2.17%. 
 
Since the company is U.S. based, we decided to use the Equity Risk Premium 
(ERP) available on Aswath Damodaran for our computations, using a value of 6%. 
This value is also approximately the historical long-run ERP in the U.S. since the 
1920s.  
 2016 2017F 2018F 2019F 2020F 2021F Perp. 
EBIT 12,006 13,784 14,652 15,575 16,556 17,599 18,251 
Interest 1,186 1,393 1,481 1,574 1,673 1,778 1,844 
D&A 5,757 5,484 5,466 5,569 5,506 5,514 5,530 
NWC 368 489 519 552 587 624 647 
CapEx 1823 1473 1564 1620 1552 1579 1584 
FCFF 15,105 16,060 16,710 17,564 18,427 19,320 19,900 
 
Table 27: DCF assumptions 
resume 
Source: AC Analysis 
  
RISK FREE RATE 2.17% 
EQUITY RISK PREMUM 6% 
BETA LEVERED 1,04 
COST OF EQUITY 10.45% 
COST OF DEBT 2.46% 
AFTER TAX COST OF 
DEBT 
1.96% 
MARGINAL TAX RATE 20% 
WEIGHT OF DEBT 15.7% 





Table 28: Alpha computation 
Source: AC Analysis 
Region Risk Premium 
Asia 1.66% 
South America 2.28% 
Europe 1.43% 









The Cost of Debt (Kd) is considered in our analysis as the effective rate that a 
company pays on its debt. We calculate the cost of debt by dividing the total interest 
expenses faced by PFE by the total debt issued. Our results in terms of Cost of Debt 
stand for 2.46%, which is also in agreement with the company’s investment grade 
rating. 
 
By analyzing the last three years of Effective Income Tax Rate of the company, we 
can observe a clear descendent trend from 25% in 2014 to 13% in 2016. Considering 
this descendent trend, but with a more conservative approach, we assume an average 
value for the Tax Rate (T) of 20%. 
 
Regarding the Terminal Value (TV), we considered that the Perpetual Growth Rate 
(g) should be a value that represents the expected percentage value of Real World 
GDP growth for the end of the forecasted period, which in this case would be 2.25%. 
For a global player such as PFE the assumption seem appropriate. Thus, the following 
expression was used: 
 
𝐓𝐕 = [𝐅𝐂𝐅𝐅 ∗ (𝟏 + 𝐠)]/[(𝐖𝐀𝐂𝐂 − 𝐠)] 
 
Multiples Valuation: 
In order to complement DCF valuation, we used the Forecast Multiples Approach to 
support our analysis to obtain the price target. As stated before several multiples were 
used in our analysis: Enterprise Value to EBITDA (EV/EBITDA), Enterprise Value to 
EBIT (EV/EBIT), Enterprise Value to Sales (EV/Sales), P/B (Price-to-Book), P/E (Price-
to-EPS) and P/Sales (Price-to-Sales). 
 
For the EV/EBITDA multiple, our computations revealed a price target of $38.35 at the 
end of 2016 representing an upside potential of 18% (Table 29). 
 
In relation to P/B, we reached a price target of $37.26 for the same period mentioned 
before, representing an upside potential of 15% (Table 30). 
 
The results obtained with Multiple Valuation, support the Discounted Cash Flow 
Valuation in what respects to the price target allowing us to conclude that Pfizer Inc. is 
currently undervalued, showing a very small difference of 1% in terms of upside 
potential when compared to DCF. With this approach, our recommendation is very 
close to the DCF one, and since 16% is a very close value to the 15% of DCF, our 
recommendation stands still for Buy. A general picture of all multiples analyzed for this 
report is displayed on Table 31. 
 
Multiples Assumptions 
At the beginning of our analysis we started with ten companies that could be potential 
Peers and after applying different criteria we selected a group of four comparable 
companies. Obeying to this criteria, the selected companies had to be U.S. based and 
equivalent in terms of size (sales, market capitalization, total assets and net income). 
Table 32 represents all Peers selected as comparable in the Multiples Valuation, and 
further information about the criteria applied is available on Appendix I. 
The summary of all multiples used in this approach is presented next in Table 33, which 
after compilation in average of all price targets resulted in an average price target of 
$37.66 and an upside potential of 16%. Table 33 is represented below.  
 
Table 29: EV/EBITDA Multiple 
Source: AC Analysis 
 2017F 
PFE EBITDA 19,267 M 
Peers Multiple 12,64 
PFE Enterprise 
Value by Peers 
243,445 M 
Net Debt 14,780 M 
Equity Value by 
Peers 
228,666 M 
Shares Outstanding 5,962 M 
Price Target $38,35 
Current Price $32,48 
Upside potential 18% 
 
Table 30: P/B Multiple 
Source: AC Analysis 
 2017F 
PFE total equity 72,799 M 
Peers Multiple 3.05 
Book Value 11.99 
Shares Outstanding 5,962 M 
Price Target $37.26 
Current Price $32.48 
Upside potential 15% 
 
Table 31: Multiples output 
Source: AC Analysis 







Average Price Target $37.66 






Table 33: Multiples output 
Source: AC Analysis  
 
Companies EV/EBITDA EV/EBIT EV/Sales P/B P/E Price/Sales 
PFE 11.88 17.18 4.19 3.05 18.32 3.92 
JNJ 11.85 14.13 3.88 4.21 17.84 4.11 
NVS 14.77 22.71 4.26 2.73 25.71 4.02 
MRK 13.83 Outlier 4.11 3.55 21.69 3.87 
SNY 10.86 17.31 3.13 1.73 23.01 2.94 
Average 12.64 17.83 3.92 3.05 21.31 3.77 
Price 
Target 
$38.35 $38.74 $34.40 $37.26 $41.70 $35.52 
 
 
Aggregating all multiples of our analysis and using all forecasted fundamentals for 
2017F, it was possible to conclude that Pfizer Inc., is undervalued, solidifying the 
conclusion from the DCF valuation. 
A summarized version that compares the different price target to current price, 
obtained from these two fundamental valuation approaches is presented in Table 34: 
 
Table 34: Summary Price Targets 



































Price Target Current Price
Table 32: Peer Analysis 
Source: AC Analysis 

















Profit & Loss 
In our analysis it is possible to see that Net Income is forecast to develop higher values 
in the future than it did in the past. This is also verified for the foreseen values of EBIT 
and EBITDA, increasing values for the future when compared to the last 3 years. This 
happens because of the assumptions made, mainly by considering Pfizer Inc. will 
increase revenues around 6% a year in the next five years, after the recent period of 
reduced growth in developed economies. When looking at forecasted values of the 
company, we can state that investments related with acquisition of fixed production 
assets or CapEx, will stay flat to the end of the period and not growing as fast as 
revenues. This happens because the company is already accustomed to have those 
expenses accounted in their cash flow statement, and it is possible to say that it 
actually benefits future values in terms of EBIT and EBITDA, since D&A are also 
forecast to stay stable for the next five years. With respect to Net Income as measure 
of Income Statement performance, we can say that Pfizer Inc. shows very reasonable 
values for the future considering the historical past of the company (Figure 30). 
EBITDA Margin shows a decrease from 38% to 33% from 2014 to 2016, and for the 
future it is predictable that this value ranges from 34% to 32%, while EBIT Margin is 
expected to have a more regular value for the future staying stable around 25%, as 
Figure 31 shows. 
 
In terms of Costs for the forecasted period, we think that the cost structure of the Pfizer 
Inc. will record similar values to those in the past, and as revenues increase, it is normal 
in our perspective to assume that the costs of goods and services and operational 
costs goes up as well. For the future, cost of goods and services represent around 
28% of total costs, while operational costs account for around 72% of total costs, for 
the next five years. 
 
Equity Ratio 
From 2014 to 2016 we can see a sizeable decrease in the equity ratio from 42.7% to 
34.9%, which means the company’s assets are being financed with higher levels of 
debt and consequently investment made by the owner’s has been decreasing. 
Following the same logic about this solvency ratio, we forecast that it will increase 
from 2016 to 2017 and stay stable from beyond.  
 
Dividend Policy 
Dividend payout ratio is an important performance ratio to measure the company’s 
sustainability. Pfizer Inc. like any other company is very careful and reluctant when 
cutting dividends, since it can drive the price of stock down and reflect a poor 
management ability. Having this in mind, Pfizer Inc. recorded a very high dividend 
payout ratio, around 100% in the last three years, leading us to conclude that the 
company is actually delivering more money to shareholders than it is earning and in 
the future the company is most likely to be forced to reduce this payout ratio. The 
currently strong cash position of Pfizer Inc. along with its well-known ability to generate 
enormous amounts of free cash every year, might keep the company aside from 
slashing its dividends soon, but the actual trend pharmaceutical companies have on 
engaging in heavy mergers and acquisitions deals could induce impacts on its balance 
sheet and triggering a dividend reduction. 
 
Return on Equity (ROE): 
Since 2012 Return on Equity been decreasing sharply, registering its lowest value in 
2015 around 11%. This weak performance of ROE comparing to other companies of 
7. Financial Analysis 
Figure 30: P&L performance 
Source: AC Analysis, Millions of US Dollars. 
 
 
Figure 31: EBIT/EBITDA Margin 
Source: AC Analysis, Millions of US Dollars 
 
 
Figure 32: Return on Equity 

































































































































the industry is derived by the weak performance of net income that accounted its lowest 
value in 2015, which sounded like an alarm especially due to the diminishing level of 
equity in the company balance sheet in that historical period, along with an increase in 
the level of debt contributed to boost the ROE, but it still had a low value though.  But, 
unlikely what happened since 2012, in 2016 shareholders received 12% profit per each 
dollar of equity invested, suggesting the company didn’t lose its ability to generate profit 
(Figure 32). Also, Return on Assets (ROA), performed the same way as ROE having 
a low performance from 2012 to 2015, and coming back up in 2016 suggesting the 
company recovered the ability to convert its assets into net profit.  
 
Table 35 provides a summarized analysis of historical indicators from the past three 
years and the forecasted values for those indicators in the period indicated before. 
 
Table 35: Summary Financial Performance 







































2014 2015 2016 2017F 2018F 2019F 2020F 2021F Perp.





Market Risk | Generic Competition (MR1) 
Competition from generic medicines is a challenge for all Pfizer Inc. products around 
the world and can have a significant impact on revenues. Upon the date of the 
expiration or loss of patent protection of the company’s products, PFE can lose the 
major portion of revenue in a very short time due to a generic version of patented 
products made by generic manufacturers. A few innovative products of Pfizer Inc. are 
expected to face generic competition in the next few years, a reality that also affects 
licensing and collaboration partners impacting co-promotion and rights to such 
products. 
 
Market Risk | Competitive Products (MR2)  
It is impossible to predict with accuracy the timing and impact resulted from the 
introduction of competitive products that treat diseases and conditions similar to those 
developed by the company. The introduction of competitive products can lead to a fall 
on sales, considering that products that compete with the company’s products are 
launched from time to time. Pfizer Inc. also produces generic and biosimilar products 
to compete with branded products from competitors, which can impact sales in case 
the company secures the position to be the first entering the market. The dependence 
on innovative products is very significant, in such a way that any issue related to it, 
despite its nature, can directly affect sales. Figure 34 contemplates an explanation on 
how generic and competitive products enter the market. 
 
Market Risk | Research & Development (MR3)  
In order to strengthen the company’s business, PFE is in constant expenditures on 
R&D to refuel product lines over time and offsetting revenue losses when products lose 
market exclusivity, assuring also earning growth. Constant investment in R&D and 
delivering return to shareholders is a big challenge, because R&D expenses may not 
be correctly matched between science and markets, leading to a failure when 
developing a new product, even though it is an effort to build an efficient and strong 
pipeline of products. There is no guarantee that the strategies in terms of R&D to 
develop new products will deliver value in the future or a satisfying result, which could 
affect profitability in the future. 
 
Regulatory and Legal Risk | Pricing (RL1) 
International and U.S. based regulations requiring price controls and limitations in 
terms of patient access to certain therapies can impact the future results of Pfizer Inc. 
At the moment there are regulatory and legislative issues in many countries concerning 
pricing pressures of the company’s products. Also, a very competitive insurance 
market puts pressure to shrink prices through more enhanced discounts and a more 
rigorous bidding or purchasing review process. Governments provide healthcare at low 
direct costs to patients and try to regulate prices aiming to control government costs in 
the healthcare system, following the global economic pressures. It is expected that 
pressures on pricing components will continue and consequently impacting the 
company’s operating results. Also, other legislation or regulation including different 
patent laws, allowance to import foreign medicines at prices regulated by other entities 
or the use of other methodologies based on cost difference might affect Pfizer Inc. 
results. 
 
Regulatory and Legal Risk | FDA Approval (RL2) 
Innovation is critical for the success of the company and the outcome of the complex 
process of developing a new product involves uncertainty, costs and risks. Products 
8. Investment Risks 
Figure 33: PFE risk matrix 
Source: AC Analysis 
 
 
Figure 34: PFE market risks 





Table 36: PFE list of medicines 
waiting for approval by FDA 








•Biosimilar to Remicade by Janseen
•Biosimilar to Herceptin by Genentech
•Biosimilar to Rituxan by Biogen
•Biosimilar to Avastin by Genentech








take many years to be approved, medicines under development can and will with high 
probability fail at any stage of the approval process. The knowledge and experience 
the company already has in the industry allows one to state that it is completely 
unpredictable the final decision of regulatory authority at each stage, depending 
exclusively on the assessment by those authorities of the benefit-risk profile suggested 
by all safety information submitted. The final decisions of FDA can significantly affect 
the commercial availability of products and there is no guarantee that the company can 
meet all FDA requirements for future approval. Also there are many considerations that 
can affect the marketing of the company products around the world, aiming basically 
safety and efficacy of products that can directly affect profits. Regulatory scrutiny by 
regulatory authorities has been increasing, with FDA and other authorities focusing on 
product safety and risk benefit profile. Table 36 shows the currently products on the 
company’s pipeline waiting for FDA approval.  
 
Regulatory and Legal Risk | Intellectual Property (RL3) 
The long-term success of the company relies on the capacity to create competitive 
products. Protecting them involves patenting, trade mark, copyright, trade secret, 
protection laws, confidentially and license agreements with employees to protect 
intellectual property and proprietary rights. Aiming to maintain an adequate intellectual 
property protection, the company seeks to prevent third parties from launching new 
products using technology and marketing strategies similar to Pfizer Inc.’s. The risks 
related with this particular matter involve probability of failure in future patent 
applications, denied patent extension, or lack of claims in patents to protect the 
company against third parties, since claims differ from country to country where 
different patent laws exist. A scenario in which the company fails to implement such 
intellectual property protection from third parties, can affect the company’s operating 
results and financial condition. 
 
Economic Risk | Global Economic Environment (ER1) 
The global economic environment didn’t have a noticeable impact until now on the 
company’s liquidity or capital resources. Regarding operating cash flows, financial 
assets, access to capital markets and availability of lines of credit the company 
currently has, it is reasonable to assume Pfizer Inc. will maintain the ability to meet its 
liquidity needs for the foreseeable future. Although there is no expectation that 
company liquidity will be affected in the future, there is no guarantee that possible 
future changes in global financial markets and global economic conditions will not 
affect capital resources or the existent capacity to obtain financing. It is impossible to 
predict the likelihood of future changes in these economic conditions or the impact they 
might have in results and financial condition of the company. 
 
Corporate Risk | Foreign Exchange Rate (CR1) 
Significant amounts of revenues, earnings and international assets are exposed to 
foreign exchange rates. In 2016, international revenues represented 50% of total 
revenues. Since Pfizer Inc. operates worldwide, it is directly exposed to multiple foreign 
currencies and changes in those currencies can impact directly revenues and 
expenses. The main financial exposure arises from short term and long term 
intercompany receivables and payables, and with less expression from investment and 
debt held in other currencies. In order to protect against longer term movements, Pfizer 
Inc. is currently hedging forecast intercompany sales in other currencies. Also, the 
company uses foreign currency swaps and foreign currency forward-exchange 
contracts to protect against possible declines in reported net investments of foreign 
business entities. Figure 35 represents the two major currencies and fluctuations 
related to U.S. Dollar. 
 
Figure 35: Historical Exchange 
Rates 



























































Corporate Risk | Interest Rate Risk (CR2) 
Pfizer Inc. is subject to interest rate risk on investments and borrowings, managing 
interest rate risk focusing on the company’s immediate liquidity needs. The company 
strives to adopt a floating rate in what respects to its investments and long term 
borrowings, which might be influenced by the risk of reduction of the short term interest 
rate, resulting in less interest income. To protect against this, the company uses 
interest rate swaps in its investment portfolio. 
 
The general risk matrix is represented in Figure 33. 
 
Risks to Price Target: 
In order to analyze the possible changes that could occur in the price target obtained 
($37.35), we perform a sensitivity analysis to assess the impact of certain key variables 
considered crucial in the DCF valuation method.  
The key variables chosen to perform the sensitivity analysis were the Terminal 
Growth Rate (g), the Weighted Average Cost of Capital (WACC), the Equity Risk 
Premium (ERP), the Levered Beta and the Income Tax Rate. 
The outcome of the sensitivity analysis performed is presented below, and represents 
the changes in current price ($32.48) according to the variation of the key variables.  
 
 
Table 37: Change in Terminal Growth Rate 





1.95% 2.05% 2.15% 2.25% 2.35% 2.45% 2.55% 
Price 
Target 
$36.16 $36.55 $36.94 $37.35 $37.77 $38.21 $38.65 
Upside 
Potential 
11.3% 12.5% 13.7% 15% 16.3% 17.6% 19% 
 
As it is possible to see in Table 37, the terminal growth rate directly influences the 
Terminal Value and consequently the Enterprise Value, and is clearly reflected on the 
price target performance. Following the investment grade matrix represented in Figure 
1, in Research Snapshot section, a lower terminal growth rate would suggest for Hold, 
since there would be a Medium risk assessment, and the opposite would happen if 
the terminal growth rate behave in an increasing way. 
 
Table 38: Change in WACC 




6.65% 7.39% 8.21% 9.12% 10.03% 11.04% 12.14% 
Price 
Target 
$59.88 $50.77 $43.39 $37.35 $32.78 $28.93 $25.67 
Upside 
Potential 
84.4% 56.3% 33.6% 15% 0.9% -10.9% -21% 
 
Also, considering WACC rate is a very important measure for DCF method, it is 





very significant changes in the price target. In Table 38, it is possible to denote that a 
higher penalty in the WACC rate would stand for a lower price target and the opposite 
would happen when the there is a lower penalty. In this case, we can say that a lower 
WACC rate would cause a risky upside potential, and a higher WACC rate would stand 
for a Reduce recommendation. 
 
Table 39: Change in ERP 





5.7% 5.8% 5.9% 6% 6.1% 6.2% 6.3% 
Price 
Target 
$38.91 $38.38 $37.86 $37.35 $36.86 $36.38 $35.91 
Upside 
Potential 
19.8% 18.2% 16.6% 15% 13.5% 12% 10.6% 
 
In our base-case scenario valuation, we considered an ERP of 6%, as suggested by 
Aswath Damodaran and in line with the long-term historical data for the United States. 
Considering an alternative range of values from 5.7% to 6.3% our valuation results in 
price targets ranging from $35.91 to $38.91, which are not substantially different from 
our base-case valuation of $37.35, and confirm the upside potential when compared 
to the current price of $32.48, justifying our Buy recommendation (Table 39). 
 
Table 40: Change in Beta 




0.89 0.94 0.98 1.04 1.09 1.14 1.2 
Price 
Target 
$42.18 $40.52 $38.91 $37.35 $35.91 $34.52 $33.17 
Upside 
Potential 
30% 25% 20% 15% 11% 6% 2% 
 
Regarding our valuation scenario we used the Unlevered Beta suggested by Aswath 
Damodaran to compute the Levered Beta (1.04) for the DCF valuation method, as 
previously stated. As we can see in Table 40, the changes in Beta are not significant 
and from a range of 0.89 to 1.2, they all suggest an upside potential and support our 
recommendation for Buy. 
 
Table 41: Change in Tax Rate 
Source: AC Analysis 
 
Tax Rate 14% 16% 18% 20% 22% 24% 26% 
Price 
Target 
$37.38 $37.37 $37.36 $37.35 $37.34 $37.34 $37.33 
Upside 
Potential 
15.08% 15.06% 15.03% 15% 14.98% 14.95% 14.92% 
 
The changes in the Tax Rate disposed on Table 41, show very small evidence that it 
might affect the price target. Ranging from 14% to 26%, is not reasonable to say that 
a difference between $37.38 and $37.33 is relevant. Moreover, the sensitivity 
analyzes performed in this specific parameter supports our Buy recommendation, 








Table 42: Change in Terminal Growth and WACC 
Source: AC Analysis 
 
 6.65% 7.39% 8.21% 9.12% 10.03% 11.04% 12.14% 
1.95% $56.6 $48.5 $41.7 $36.1 $31.9 $28.3 $25.2 
2.05% $57.7 $49.2 $42.3 $36.5 $32.2 $28.5 $25.3 
2.15% $58.7 $50 $42.8 $36.9 $32.5 $28.7 $25.5 
2.25% $59.9 $50.8 $43.4 $37.3 $32.8 $28.9 $25.7 
2.35% $61.1 $51.6 $44 $37.8 $33.1 $29.2 $25.8 
2.45% $62.3 $52.5 $44.6 $38.2 $33.4 $29.4 $26 
2.55% $63.6 $53.4 $45.2 $38.6 $33.7 $29.6 $26.2 
 
Table 42 summarizes the impact of Terminal Growth Rate and WACC rate together, 
and it is possible to see that both parameters indicate for a downside potential 
whenever WACC rate is higher than 10.03%, and an upside potential whenever is 
lower than 10.03%.  
 
Table 43: Change in Beta and ERP 
Source: AC Analysis 
 
 0.89 0.94 0.98 1.04 1.09 1.14 1.2 
5.7% $43.88 $42.18 $40.52 $38.91 $37.43 $35.99 $34.59 
5.8% $43.30 $41.61 $39.97 $38.38 $36.91 $35.48 $34.10 
5.9% $42.73 $41.06 $39.43 $37.86 $36.40 $34.99 $33.63 
6% $42.18 $40.52 $38.91 $37.35 $35.91 $34.52 $33.17 
6.1% $41.64 $40 $38.40 $36.86 $35.44 $34.06 $32.72 
6.2% $41.11 $39.49 $37.91 $36.38 $34.97 $33.61 $32.29 
6.3% $40.60 $38.99 $37.43 $35.91 $34.52 $33.17 $31.86 
 
Table 43 summarizes the impact of changes in Beta and ERP together, and as we can 
see the impacts of both parameters is almost insignificant in a range of values from 
0.89 to 1.2 in terms of Beta and from 5.7% to 6.3% in terms of ERP. The table reveal 
an upside potential supporting our recommendation of Buy.  
 
After performing the sensitive analysis, we analyze possible outcomes in the price 
target when some parameters involved in the valuation method change. We conclude 
that the WACC rate used in the valuation method is the most sensible parameter, and 
the one that most influences the price target performance. On the other hand, the 
parameter that has almost an insignificant influence in the price target is the variation 





















2014 2015 2016 2017F 2018F 2019F 2020F 2021F Perpetuity
Total Assets
  Cash, Cash Equivalents & STI 36,122 23,290 17,850 28,878 30,698 32,632 34,687 36,873 37,868
    Cash & Cash Equivalents 3,343 3,641 2,595 3,576 3,801 4,041 4,295 4,566 4,689
    ST Investments 32,779 19,649 15,255 25,302 26,896 28,591 30,392 32,307 33,179
  Accounts & Notes Receiv 8,401 8,176 8,225 9,217 9,798 10,415 11,071 11,768 12,086
    Accounts Receivable, Net 8,401 8,176 8,225 9,217 9,798 10,415 11,071 11,768 12,086
    Notes Receivable, Net — — — — — — — — —
  Inventories 5,663 7,513 6,783 7,419 7,886 8,383 8,911 9,473 9,728
    Raw Materials 510 867 793 806 856 910 968 1,029 1,056
    Work In Process 3,248 3,932 3,696 4,042 4,296 4,567 4,855 5,161 5,300
    Finished Goods 1,905 2,714 2,294 2,572 2,734 2,906 3,089 3,283 3,372
    Other Inventory — — — — — — — — —
  Other ST Assets 5,409 4,825 6,091 6,048 6,429 6,834 7,264 7,722 7,931
    Derivative & Hedging Assets 1,059 586 566 825 877 932 991 1,053 1,081
    Assets Held-for-Sale — 9 801 — — — — — —
    Deferred Tax Assets 2,566 2,662 3,041 3,066 3,259 3,464 3,682 3,914 4,020
    Taxes Receivable — — — — — — — — —
    Discontinued Operations — — — — — — — — —
    Misc ST Assets 1,784 1,568 1,683 1,870 1,988 2,113 2,246 2,388 2,452
Total Current Assets 55,595 43,804 38,949 51,562 54,810 58,263 61,934 65,836 67,613
  Property, Plant & Equip, Net 11,760 13,766 13,318 14,431 15,340 16,306 17,334 18,426 18,923
    Property, Plant & Equip 24,986 27,268 28,125 29,841 31,721 33,720 35,844 38,102 39,131
    Accumulated Depreciation 13,226 13,502 14,807 15,410 16,381 17,413 18,510 19,677 20,208
  LT Investments & Receivables 17,518 15,999 7,116 15,261 16,223 17,245 18,331 19,486 20,012
    LT Investments 17,518 15,999 7,116 15,261 16,223 17,245 18,331 19,486 20,012
  Other LT Assets 82,692 93,812 112,232 106,914 113,649 120,809 128,420 136,510 140,196
    Total Intangible Assets 77,236 88,598 107,097 101,038 107,403 114,169 121,362 129,008 132,491
    Goodwill 42,069 48,242 54,449 53,651 57,031 60,624 64,443 68,503 70,353
    Other Intangible Assets 35,167 40,356 52,648 47,387 50,372 53,546 56,919 60,505 62,139
    Deferred Tax Assets 1,944 1,794 1,812 2,063 2,193 2,331 2,478 2,634 2,705
    Derivative & Hedging Assets 881 944 689 938 997 1,060 1,127 1,198 1,230
    Prepaid Pension Costs — 572 300 — — — — — —
    Misc LT Assets 2,632 1,904 2,334 2,550 2,710 2,881 3,063 3,255 3,343
Total Noncurrent Assets 111,970 123,577 132,666 136,606 145,212 154,360 164,085 174,423 179,132
Total Assets 167,566 167,381 171,615 188,168 200,023 212,624 226,020 240,259 246,746
Liabilities & Shareholders' Equity
  Payables & Accruals 7,293 8,249 9,404 9,245 9,827 10,446 11,104 11,804 12,122
    Accounts Payable 3,210 3,620 4,536 4,205 4,470 4,752 5,051 5,370 5,515
    Accrued Taxes 531 418 437 515 548 582 619 658 676
    Interest & Dividends Payable 1,711 1,852 1,944 2,044 2,173 2,310 2,455 2,610 2,680
    Other Payables & Accruals 1,841 2,359 2,487 2,480 2,636 2,802 2,979 3,166 3,252
  ST Debt 5,141 10,159 10,688 9,619 10,225 10,870 11,554 12,282 12,614
    ST Borrowings 2,130 6,439 6,463 5,561 5,911 6,284 6,679 7,100 7,292
    ST Capital Leases
    Current Portion of LT Debt 3,011 3,720 4,225 4,059 4,314 4,586 4,875 5,182 5,322
  Other ST Liabilities 9,153 10,990 11,023 11,570 12,299 13,074 13,898 14,773 15,172
    Deferred Revenue 0
    Derivatives & Hedging 92 645 1,247 724 769 818 869 924 949
    Discontinued Operations — — — — — — — — —
    Misc ST Liabilities 9,061 10,345 9,776 10,847 11,530 12,256 13,028 13,849 14,223
Total Current Liabilities 21,587 29,398 31,115 30,434 32,352 34,390 36,556 38,859 39,909
  LT Debt 31,541 28,740 31,398 34,038 36,183 38,462 40,885 43,461 44,635
    LT Borrowings 31,541 28,740 31,398 34,038 36,183 38,462 40,885 43,461 44,635
    LT Capital Leases
  Other LT Liabilities 42,817 44,245 49,262 50,564 53,749 57,135 60,735 64,561 66,304
    Accrued Liabilities
    Pension Liabilities 10,264 8,119 8,172 9,879 10,502 11,163 11,867 12,614 12,955
    Deferred Revenue
    Deferred Tax Liabilities 23,317 26,877 30,753 29,993 31,882 33,891 36,026 38,296 39,330
    Derivatives & Hedging 597 1,062 444 789 839 892 948 1,008 1,035
    Misc LT Liabilities 8,639 8,187 9,893 9,902 10,526 11,189 11,894 12,643 12,985
Total Noncurrent Liabilities 74,358 72,985 80,660 84,602 89,932 95,598 101,620 108,022 110,939
Total Liabilities 95,945 102,383 111,775 115,036 122,284 129,988 138,177 146,882 150,848
  Preferred Equity and Hybrid Capital 29 26 24 29 31 33 35 38 39
  Share Capital & APIC 79,432 81,475 83,146 90,650 96,361 102,432 108,885 115,745 118,870
    Common Stock 455 459 461 511 543 577 614 652 670
    Additional Paid in Capital 78,977 81,016 82,685 90,140 95,818 101,855 108,272 115,093 118,200
  Treasury Stock 73,021 79,252 84,364 87,811 93,343 99,224 105,475 112,120 115,147
  Retained Earnings 72,176 71,993 71,774 80,250 85,306 90,680 96,393 102,466 105,232
  Other Equity -7,316 -9,522 -11,036 -10,319 -10,969 -11,660 -12,395 -13,176 -13,532
Equity Before Minority Interest 71,300 64,720 59,544 72,799 77,386 82,261 87,443 92,952 95,462
  Minority/Non Controlling Interest 321 278 296 333 353 376 399 425 436
Total Equity 71,621 64,998 59,840 73,132 77,739 82,637 87,843 93,377 95,898





































2014 2015 2016 2017F 2018F 2019F 2020F 2021F Perpetuity
Revenue 49,605 48,851 52,824 56,152 59,689 63,450 67,447 71,696 73,632
    Sales & Services Revenue 49,605 48,851 52,824 56,152 59,689 63,450 67,447 71,696 73,632
  Cost of Revenue 9,577 9,648 12,329 11,679 12,415 13,197 14,028 14,912 15,315
    Cost of Goods & Services 9,577 9,648 12,329 11,679 12,415 13,197 14,028 14,912 15,315
Gross Profit 40,028 39,203 40,495 44,473 47,275 50,253 53,419 56,785 58,318
  Other Operating Income — — — — — — — — —
  Operating Expenses 26,779 27,379 28,489 30,689 32,623 34,678 36,863 39,185 40,243
    Selling, General & Admin 14,097 14,809 14,837 16,251 17,274 18,363 19,519 20,749 21,309
    Research & Development 8,393 7,690 7,872 8,903 9,464 10,060 10,693 11,367 11,674
    Depreciation & Amortization 4,039 3,728 — 2,952 3,138 3,336 3,546 3,770 3,872
    Other Operating Expense 250 1,152 5,780 2,584 2,747 2,920 3,104 3,299 3,388
Operating Income (Loss) 13,249 11,824 12,006 13,784 14,652 15,575 16,556 17,599 18,075
  Non-Operating (Income) Loss 1,009 2,859 3,655 2,771 2,946 3,131 3,329 3,538 3,634
    Interest Expense, Net 935 728 716 885 941 1,001 1,064 1,131 1,161
    Interest Expense 1,360 1,199 1,186 1,393 1,481 1,574 1,673 1,778 1,826
    Interest Income 425 471 470 507 539 573 609 648 665
    Foreign Exch (Gain) Loss 0 806 0 309 328 349 371 394 405
    (Income) Loss from Affiliates — — — — — — — — —
    Other Non-Op (Income) Loss 74 1,325 2,939 1,577 1,676 1,782 1,894 2,014 2,068
Pretax Income 12,240 8,965 8,351 11,012 11,706 12,444 13,228 14,061 14,441
  Income Tax Expense (Benefit) 3,121 1,990 1,123 2,338 2,485 2,642 2,808 2,985 3,066
    Current Income Tax 2,799 2,010 1,823 2,472 2,628 2,794 2,970 3,157 3,242
    Deferred Income Tax 322 -20 -700 -134 -143 -152 -161 -171 -176
    Tax Allowance/Credit — — — — — — — — —
Income (Loss) from Cont Ops 9,119 6,975 7,228 8,674 9,221 9,802 10,419 11,076 11,375
  Net Extraordinary Losses (Gains) -48 -11 -18 -29 -31 -32 -34 -37 -38
    Discontinued Operations -48 -11 -18 -29 -31 -32 -34 -37 -38
    XO & Accounting Changes — — — — — — — — —
Income (Loss) Incl. MI 9,167 6,986 7,246 8,703 9,251 9,834 10,454 11,112 11,412
  Minority Interest 32 26 31 33 35 37 40 42 43
Net Income, GAAP 9,135 6,960 7,215 8,670 9,216 9,797 10,414 11,070 11,369
  Preferred Dividends 2 2 2 2 2 3 3 3 3
  Other Adjustments — — — — — — — — —






















2014 2015 2016 2017F 2018F 2019F 2020F 2021F Perpetuity
Cash from Operating Activities
  Net Income 9,135 6,960 7,215 8,670 9,216 9,797 10,414 11,070 11,369
  Depreciation & Amortization 5,537 5,157 5,757 6,105 6,490 6,899 7,333 7,795 8,006
  Non-Cash Items 1,151 2,724 2,561 2,385 2,536 2,695 2,865 3,046 3,128
    Stock-Based Compensation 586 669 691 722 768 816 868 922 947
    Deferred Income Taxes 317 -18 -700 -135 -144 -153 -163 -173 -177
    Other Non-Cash Adj 248 2,073 2,570 1,798 1,912 2,032 2,160 2,296 2,358
  Chg in Non-Cash Work Cap 1,111 -159 368 489 519 552 587 624 641
    (Inc) Dec in Accts Receiv 148 21 -134 16 17 19 20 21 22
    (Inc) Dec in Inventories 175 -199 365 119 127 135 143 152 156
    Inc (Dec) in Accts Payable 297 254 871 518 551 585 622 661 679
    Inc (Dec) in Other 491 -235 -734 -165 -175 -186 -198 -210 -216
  Net Cash From Disc Ops -51 6 0 -17 -18 -19 -20 -22 -22
Cash from Operating Activities 16,883 14,688 15,901 17,632 18,743 19,924 21,179 22,514 23,121
Cash from Investing Activities
  Change in Fixed & Intang -1,199 -1,496 -1,999 -1,734 -1,843 -1,959 -2,083 -2,214 -2,274
    Disp in Fixed & Intang — — — — — — — — —
    Disp of Fixed Prod Assets — — — — — — — — —
    Disp of Intangible Assets — — — — — — — — —
    Acq of Fixed & Intang -1,199 -1,496 -1,999 -1,734 -1,843 -1,959 -2,083 -2,214 -2,274
    Acq of Fixed Prod Assets -1,199 -1,397 -1,823 -1,634 -1,737 -1,846 -1,962 -2,086 -2,142
    Acq of Intangible Assets 0 -99 -176 -100 -107 -113 -120 -128 -132
  Net Change in LT Investment -4,573 -2,613 3,243 -1,578 -1,677 -1,783 -1,895 -2,014 -2,069
    Dec in LT Investment 6,145 6,929 11,254 8,961 9,526 10,126 10,764 11,442 11,751
    Inc in LT Investment -10,718 -9,542 -8,011 -10,539 -11,203 -11,908 -12,659 -13,456 -13,820
  Net Cash From Acq & Div -579 -16,466 -18,368 -13,036 -13,857 -14,730 -15,658 -16,645 -17,094
    Cash from Divestitures 0 0 0 0 0 0 0 0 0
    Cash for Acq of Subs -579 -16,466 -18,368 -13,036 -13,857 -14,730 -15,658 -16,645 -17,094
    Cash for JVs 0 0 0 0 0 0 0 0 0
  Other Investing Activities 697 17,595 9,313 10,304 10,954 11,644 12,377 13,157 13,512
Cash from Investing Activities -5,654 -2,980 -7,811 -6,043 -6,424 -6,828 -7,258 -7,716 -7,924
Cash from Financing Activities
  Dividends Paid -6,609 -6,940 -7,317 -7,745 -8,233 -8,752 -9,304 -9,890 -10,157
  Cash From (Repayment) Debt 549 1,319 2,573 1,624 1,727 1,835 1,951 2,074 2,130
    Cash From (Repay) ST Debt -1,838 4,309 -714 704 749 796 846 899 924
    Cash From LT Debt 4,491 0 10,976 5,584 5,936 6,309 6,707 7,129 7,322
    Repayments of LT Debt -2,104 -2,990 -7,689 -4,664 -4,958 -5,270 -5,602 -5,955 -6,116
  Cash (Repurchase) of Equity -3,998 -4,897 -3,981 -4,795 -5,098 -5,419 -5,760 -6,123 -6,288
    Increase in Capital Stock 1,002 1,263 1,019 1,223 1,300 1,382 1,469 1,562 1,604
    Decrease in Capital Stock -5,000 -6,160 -5,000 -6,019 -6,398 -6,801 -7,229 -7,685 -7,892
  Other Financing Activities 72 109 -196 -1 -1 -1 -1 -1 -1
Cash from Financing Activities -9,986 -10,409 -8,921 -10,917 -11,605 -12,336 -13,113 -13,939 -14,316
  Effect of Foreign Exchange Rates -83 -1,000 -215 -491 -522 -554 -589 -626 -643
Net Changes in Cash 1,160 299 -1,046 182 193 205 218 232 238
Cash Paid for Taxes 2,100 2,383 2,521 2,599 2,762 2,936 3,121 3,318 3,408













2014 2015 2016 2017F
Total Assets
  Cash, Cash Equivalents & STI 21.56% 13.91% 10.40% 15.35%
    Cash & Cash Equivalents 2.00% 2.18% 1.51% 1.90%
    ST Investments 19.56% 11.74% 8.89% 13.45%
  Accounts & Notes Receiv 5.01% 4.88% 4.79% 4.90%
    Accounts Receivable, Net 5.01% 4.88% 4.79% 4.90%
    Notes Receivable, Net — — — —
  Inventories 3.38% 4.49% 3.95% 3.94%
    Raw Materials 0.30% 0.52% 0.46% 0.43%
    Work In Process 1.94% 2.35% 2.15% 2.15%
    Finished Goods 1.14% 1.62% 1.34% 1.37%
    Other Inventory 0.00% 0.00% 0.00% 0.00%
  Other ST Assets 3.23% 2.88% 3.55% 3.21%
    Derivative & Hedging Assets 0.63% 0.35% 0.33% 0.44%
    Assets Held-for-Sale — 0.01% 0.47% 0.00%
    Deferred Tax Assets 1.53% 1.59% 1.77% 1.63%
    Taxes Receivable — — — —
    Discontinued Operations — — — —
    Misc ST Assets 1.06% 0.94% 0.98% 0.99%
Total Current Assets 33.18% 26.17% 22.70% 27.40%
  Property, Plant & Equip, Net 7.02% 8.22% 7.76% 7.67%
    Property, Plant & Equip 14.91% 16.29% 16.39% 15.86%
    Accumulated Depreciation 7.89% 8.07% 8.63% 8.19%
  LT Investments & Receivables 10.45% 9.56% 4.15% 8.11%
    LT Investments 10.45% 9.56% 4.15% 8.11%
  Other LT Assets 49.35% 56.05% 65.40% 56.82%
    Total Intangible Assets 46.09% 52.93% 62.41% 53.70%
    Goodwill 25.11% 28.82% 31.73% 28.51%
    Other Intangible Assets 20.99% 24.11% 30.68% 25.18%
    Deferred Tax Assets 1.16% 1.07% 1.06% 1.10%
    Derivative & Hedging Assets 0.53% 0.56% 0.40% 0.50%
    Prepaid Pension Costs — 0.34% 0.17% 0.00%
    Misc LT Assets 1.57% 1.14% 1.36% 1.35%
Total Noncurrent Assets 66.82% 73.83% 77.30% 72.60%
Total Assets 100.00% 100.00% 100.00% 100.00%
Liabilities & Shareholders' Equity
  Payables & Accruals 4.35% 4.93% 5.48% 4.91%
    Accounts Payable 1.92% 2.16% 2.64% 2.23%
    Accrued Taxes 0.32% 0.25% 0.25% 0.27%
    Interest & Dividends Payable 1.02% 1.11% 1.13% 1.09%
    Other Payables & Accruals 1.10% 1.41% 1.45% 1.32%
  ST Debt 3.07% 6.07% 6.23% 5.11%
    ST Borrowings 1.27% 3.85% 3.77% 2.96%
    ST Capital Leases 0.00% 0.00% 0.00% 0.00%
    Current Portion of LT Debt 1.80% 2.22% 2.46% 2.16%
  Other ST Liabilities 5.46% 6.57% 6.42% 6.15%
    Deferred Revenue 0.00% 0.00% 0.00% 0.00%
    Derivatives & Hedging 0.05% 0.39% 0.73% 0.38%
    Discontinued Operations — — — —
    Misc ST Liabilities 5.41% 6.18% 5.70% 5.76%
Total Current Liabilities 12.88% 17.56% 18.13% 16.17%
  LT Debt 18.82% 17.17% 18.30% 18.09%
    LT Borrowings 18.82% 17.17% 18.30% 18.09%
    LT Capital Leases 0.00% 0.00% 0.00% 0.00%
  Other LT Liabilities 25.55% 26.43% 28.70% 26.87%
    Accrued Liabilities 0.00% 0.00% 0.00% 0.00%
    Pension Liabilities 6.13% 4.85% 4.76% 5.25%
    Deferred Revenue 0.00% 0.00% 0.00% 0.00%
    Deferred Tax Liabilities 13.92% 16.06% 17.92% 15.94%
    Derivatives & Hedging 0.36% 0.63% 0.26% 0.42%
    Misc LT Liabilities 5.16% 4.89% 5.76% 5.26%
Total Noncurrent Liabilities 44.38% 43.60% 47.00% 44.96%
Total Liabilities 57.26% 61.17% 65.13% 61.13%
  Preferred Equity and Hybrid Capital 0.02% 0.02% 0.01% 0.02%
  Share Capital & APIC 47.40% 48.68% 48.45% 48.18%
    Common Stock 0.27% 0.27% 0.27% 0.27%
    Additional Paid in Capital 47.13% 48.40% 48.18% 47.90%
  Treasury Stock 43.58% 47.35% 49.16% 46.67%
  Retained Earnings 43.07% 43.01% 41.82% 42.65%
  Other Equity -4.37% -5.69% -6.43% -5.48%
Equity Before Minority Interest 42.55% 38.67% 34.70% 38.69%
  Minority/Non Controlling Interest 0.19% 0.17% 0.17% 0.18%
Total Equity 42.74% 38.83% 34.87% 38.87%







































2014 2015 2016 2017F
Revenue 100.00% 100.00% 100.00% 100.00%
    Sales & Services Revenue 100.00% 100.00% 100.00% 100.00%
  Cost of Revenue 19.31% 19.75% 23.34% 20.80%
    Cost of Goods & Services 19.31% 19.75% 23.34% 20.80%
Gross Profit 80.69% 80.25% 76.66% 79.20%
  Other Operating Income — — — —
  Operating Expenses 53.98% 56.05% 53.93% 54.65%
    Selling, General & Admin 28.42% 30.31% 28.09% 28.94%
    Research & Development 16.92% 15.74% 14.90% 15.85%
    Depreciation & Amortization 8.14% 7.63% — 5.26%
    Other Operating Expense 0.50% 2.36% 10.94% 4.60%
Operating Income (Loss) 26.71% 24.20% 22.73% 24.55%
  Non-Operating (Income) Loss 2.03% 5.85% 6.92% 4.94%
    Interest Expense, Net 1.88% 1.49% 1.36% 1.58%
    Interest Expense 2.74% 2.45% 2.25% 2.48%
    Interest Income 0.86% 0.96% 0.89% 0.90%
    Foreign Exch (Gain) Loss 0.00% 1.65% 0.00% 0.55%
    (Income) Loss from Affiliates — — — —
    Other Non-Op (Income) Loss 0.15% 2.71% 5.56% 2.81%
Pretax Income 24.67% 18.35% 15.81% 19.61%
  Income Tax Expense (Benefit) 6.29% 4.07% 2.13% 4.16%
    Current Income Tax 5.64% 4.11% 3.45% 4.40%
    Deferred Income Tax 0.65% -0.04% -1.33% -0.24%
    Tax Allowance/Credit — — — —
Income (Loss) from Cont Ops 18.38% 14.28% 13.68% 15.45%
  Net Extraordinary Losses (Gains) -0.10% -0.02% -0.03% -0.05%
    Discontinued Operations -0.10% -0.02% -0.03% -0.05%
    XO & Accounting Changes — — — —
Income (Loss) Incl. MI 18.48% 14.30% 13.72% 15.50%
  Minority Interest 0.06% 0.05% 0.06% 0.06%
Net Income, GAAP 18.42% 14.25% 13.66% 15.44%
  Preferred Dividends 0.00% 0.00% 0.00% 0.00%
  Other Adjustments — — — —




















2014 2015 2016 2017F
Liquidity Ratios
Current Ratio (x) 2.58 1.49 1.25 1.69
Quick Ratio (x) 2.06 1.07 0.84 1.25
Cash Ratio (x) 1.67 0.79 0.57 0.95
Solvency Ratios
Long term debt ratio (%) 44% 44% 52% 47%
Long and short term debt ratio (%) 51% 60% 70% 60%
Interest Coverage (x) 9.74 9.86 10.12 9.9
Debt to Equity (x) 1.34 1.58 1.87 1.57
Equity Ratio (%) 43% 39% 35% 39%
Equity Multiplier (x) 2.34 2.58 2.87 2.57
Profitability Ratios
Gross Margin (%) 80.69% 80.25% 76.66% 79.20%
EBIT Margin (%) 26.71% 24.20% 22.73% 24.55%
EBITDA Margin (%) 37.87% 34.76% 33.63% 34.31%
Net Profit Margin (%) 18.42% 14.25% 13.66% 15.44%
ROA (%) 5.45% 4.16% 4.20% 4.61
ROE (%) 12.75% 10.71% 12.05% 11.86%
EPS (x) 1.44 1.13 1.18 1.39
Efficiency Ratios
Total Assets Turnover (x) 0.3 0.29 0.31 0.3
Accounts receivable turnover (x) 5.9 5.97 6.42 6.09
Accounts paybale turnover (x) 2.82 3.37 2.84 2.82
Inventory turnover (x) 1.62 1.46 1.72 1.64
P&L Description
2017F 2018F 2019F 2020F 2021F Perp.
Revenues Sum of IH and EH segment revenues
Cost of Revenue 21% 21% 21% 21% 21% 21% Percentage of Revenues
Operating Expenses 55% 55% 55% 55% 55% 55% Percentage of Revenues
Selling, General Admin. Expenses 53% 53% 53% 53% 53% 53% Percentage of Operating Expenses
R&D Expenses 29% 29% 29% 29% 29% 29% Percentage of Operating Expenses
D&A 10% 10% 10% 10% 10% 10% Percentage of Operating Expenses
Other Operating Expenses 8% 8% 8% 8% 8% 8% Percentage of Operating Expenses
Non-Operating Income 5% 5% 5% 5% 5% 5% Percentage of Revenues
Interest Expense 50% 50% 50% 50% 50% 50% Percentage of Non-Operating Expenses
Interest Income 18% 18% 18% 18% 18% 18% Percentage of Non-Operating Expenses
Foreign Exchange Gain 11% 11% 11% 11% 11% 11% Percentage of Non-Operating Expenses
Income from afiliates Equal to 2016 nominal Value
Other Non Operational Income 3% 3% 3% 3% 3% 3% Percentage of Revenues
Income Tax Expense 20% 20% 20% 20% 20% 20% Average of last 3 years and forecasted values








Appendix H: DCF Valuation 
 
The target stock price of Pfizer Inc. was forecasted using the Discounted Cash Flow Method (DCF) as the main model. 
Moreover, we also applied the Relative Valuation Method to compare results and support the price target results. 
 
Discounted Cash Flow is used to compute the fair market value of a business, discounting the free cash flow to the firm 
(FCFF) and providing an accurate estimation of a company’s future level of borrowing during the forecasted period. FCFF is the 
cash available to satisfy investors that currently hold claims related to the company resources, namely stockholders, lenders 
and preferred stockholders. FCFF can be computed according to the following expression: 
 
𝑭𝑪𝑭𝑭 = 𝑬𝑩𝑰𝑻 ∗  (𝟏 − 𝑻𝒂𝒙 𝑹𝒂𝒕𝒆) + 𝑫&𝑨 − 𝑪𝒂𝒑𝑬𝒙 −  𝚫𝐍𝐖𝐂 
 
Considering this definition of FCFF, only cash flows from operating activities are considered. The Tax Rate considered can be 





2017F 2018F 2019F 2020F 2021F Perp.
Current Assets 27% 27% 27% 27% 27% 27% Percentage of Total Assets
Cash and Cash Equivalents 7% 7% 7% 7% 7% 7% Percentage of Current Assets
Shor-term investments 49% 49% 49% 49% 49% 49% Percentage of Current Assets
Trade Accounts receivable 18% 18% 18% 18% 18% 18% Percentage of Current Assets
Inventories 14% 14% 14% 14% 14% 14% Percentage of Current Assets
Other Assets 12% 12% 12% 12% 12% 12% Percentage of Current Assets
Assets held for sale Equal to 2016 nominal value
Non Current Assets 73% 73% 73% 73% 73% 73% Percentage of Total Assets
Long-term investments 11% 11% 11% 11% 11% 11% Percentage of Non Current Assets
Property, Plant and Equipment 11% 11% 11% 11% 11% 11% Percentage of Non Current Assets
Identifiable intangible assets 78% 78% 78% 78% 78% 74% Percentage of Non Current Assets
Total Assets 335% 335% 335% 335% 335% 335% Percentage of Revenues
Current Liabilities 26% 26% 26% 26% 26% 26% Percentage of Total Liabilities
Short-term borrowings 32% 32% 32% 32% 32% 32% Percentage of Current Liabilities
Trade accounts payable 30% 30% 30% 30% 30% 30% Percentage of Current Liabilities
Other Short-term liabilities 38% 38% 38% 38% 38% 38% Percentage of Current Liabilities
Non Current Liabilities 74% 74% 74% 74% 74% 74% Percentage of Total Liabilities
Long-term debt 40% 40% 40% 40% 40% 40% Percentage of Non Current Liabilities
Other Long-term debt 60% 60% 60% 60% 60% 60% Percentage of Non Current Liabilities
Total Liabilities 205% 205% 205% 205% 205% 205% Percentage of Revenues
Prefered Equity and Hybrid Capital 0,04% 0,04% 0,04% 0,04% 0,04% 0,04% Percentage of Equity
Share Capital 124% 124% 124% 124% 124% 124% Percentage of Equity
Treasury Stock 120% 120% 120% 120% 120% 120% Percentage of Equity
Retained Earnings 110% 110% 110% 110% 110% 110% Percentage of Equity
Other Equity -14% -14% -14% -14% -14% -14% Percentage of Equity
Minority interest 0,5% 0,5% 0,5% 0,5% 0,5% 0,5% Percentage of Equity








The discount rate used to discount the FCFF is the Weighted Average Cost of Capital (WACC), which represents basically 
the company’s cost of fund and the return investors require to buy common and preferred stock and bonds of the company. 
WACC is determined using the next formula, disregarding the presence of preferred stock: 
 






∗ (𝟏 − 𝒕) 
 
 
In which, Cost of Equity (Ke) stands for the minimum rate of return required to induce investors to buy the company’s equity. 
The cost of equity is usually estimated and computed using the Capital Asset Pricing Model (CAPM), balancing expected return 
and risk. In this work, we used the following expression do determine cost of equity: 
 
𝐊𝐞 =  𝐑𝐟 + 𝛃𝐥 ∗ 𝐄𝐑𝐏 +  𝛂 
 
The Risk-Free Rate (Rf) is the return for an investor who usually invest in riskless assets, consequently the more riskless 
investment is considered to be the U.S. Treasury Bond, which was used in our computations. 
 
The Levered Beta was computed using the Unlevered Beta for this industry by Aswath Damodaran, and the actual level of 
debt the company currently has. Also the Equity Risk Premium was extracted from Aswath Damodaran website. The Alpha 
term considered represents a penalization on our cost of equity, regarding the company operations worldwide that account for 
an extra risk factor that should be accounted for since not all operations are U.S. based (see e.g., Godfrey and Espinosa 1996). 
 
Cost of Debt (Kd), is the cost the company faces when financing itself with borrowed funds. In our analysis and valuation 
procedures, we considered that the cost of debt would be the average yield of already issued bonds of the company, which 





2014 2015 2016 2017F 2018F 2019F 2020F 2021F Perpetuity
Revenues 49,605 48,851 52,824 56,152 59,689 63,450 67,447 71,696 73,632
Cost of Goods Sold 9,577 9,648 12,329 11,679 12,415 13,197 14,028 14,912 15,315
Operating Expenses 26,779 27,379 28,489 30,689 32,623 34,678 36,863 39,185 40,243
Operating Income or Losses (EBIT) 13,249 11,824 12,006 13,784 14,652 15,575 16,556 17,599 18,075
Depreciation & Amortization 5,537 5,157 5,757 5,484 5,466 5,569 5,506 5,514 5,530
EBITDA 18,786 16,981 17,763 19,267 20,118 21,144 22,063 23,113 23,604
Effective Tax Rate 0 0 0 0 0 0 0 0 0
Average Effective Tax Rate 0 0 0 0 0 0 0 0 0
Interest Expense 1,360 1,199 1,186 1,393 1,481 1,574 1,673 1,778 1,826
Depreciation & Amortization 5,537 5,157 5,757 5,484 5,466 5,569 5,506 5,514 5,530
CapEx -1,199 -1,397 -1,823 -1,473 -1,564 -1,620 -1,552 -1,579 -1,584
Changes in Working Capital 1,111 -159 368 489 519 552 587 624 641
Net Cash from discontinued operations -51 6 0 -17 -18 -19 -20 -22 -22
Other operating adjustments 1,151 2,724 2,561 1,798 1,912 2,032 2,160 2,296 2,358
Net income 9,135 6,960 7,215 8,670 9,216 9,797 10,414 11,070 11,369
FCF 15,684 13,291 14,078 14,951 15,531 16,311 17,095 17,904 18,292
Interest Expense 1,360 1,199 1,186 1,393 1,481 1,574 1,673 1,778 1,826
Effective Tax Rate 1,013 933 1,027 1,109 1,179 1,253 1,332 1,416 1,454
FCFF 16,697 14,224 15,105 16,060 16,710 17,564 18,427 19,320 19,746
2014 2015 2016 2017F 2018F 2019F 2020F 2021F Perpetuity
Risk Free Rate 2.17% 2.17% 2.17% 2.17% 2.17% 2.17% 2.17% 2.17% 2.17%
Cost of Debt (Kd) 2.46% 2.46% 2.46% 2.46% 2.46% 2.46% 2.46% 2.46% 2.46%
Equity Risk Premium 6.00% 6.00% 6.00% 6.00% 6.00% 6.00% 6.00% 6.00% 6.00%
Unlevered Beta for industry 0.89 0.89 0.89 0.89 0.89 0.89 0.89 0.89 0.89
Levered Beta for industry 1.04 1.04 1.04 1.04 1.04 1.04 1.04 1.04 1.04
Cost of Equity (Ke) 10.45% 10.45% 10.45% 10.45% 10.45% 10.45% 10.45% 10.45% 10.45%
Weight of Debt 15.7% 15.3% 16.0% 15.7% 15.7% 15.7% 15.7% 15.7% 15.7%










Appendix I: Relative Valuation 
 
The first step for choosing the peer group consisted in consulting Thomson Reuters platform to extract possible comparable 
companies in this industry, with headquarters in the United States. The following table provides the information about the 
companies that satisfy this criterion: 
 
Company Name Headquarters 
Brystol-Myers Squibb (BMY) U.S. 
Eli Lilly (LLY) U.S. 
Allergan (AGN) U.S. 
AstraZeneca (AZN) U.S. 
Novo Nordisk (NVO) U.S. 
Johnson & Johnson (JNJ) U.S. 
Novartis (NVS) U.S. 
GlaxoSmithKline (GSK) U.S. 
Merck (MRK) U.S. 
Sanofi (SNY) U.S. 
 
The second step, was to compare companies in terms of size by analyzing sales, market capitalization, total assets, net income 
and EBITDA. We considered that the best comparable companies would be those that fulfilled at least three of the parameters 
selected. 
 
In terms of Sales, Pfizer Inc. recorded in 2016 $52,824 M, and according to our analysis only four companies are considered 





Company Name Sales 
Brystol-Myers Squibb (BMY) 19,427 
Eli Lilly (LLY) 21,222 
Allergan (AGN) 14,571 
AstraZeneca (AZN) 23,002 
Novo Nordisk (NVO) 111,780 
Johnson & Johnson (JNJ) 71,890 
Novartis (NVS) 48,518 
GlaxoSmithKline (GSK) 27,889 
Merck (MRK) 39,807 
Sanofi (SNY) 34,708 
 
In what concerns to market capitalization, Pfizer Inc. has approximately $197,154 M. The following table provides peers that 


















Company Name Market Capitalization 
Brystol-Myers Squibb (BMY) 97,244 
Eli Lilly (LLY) 80,969 
Allergan (AGN) 70,332 
AstraZeneca (AZN) 69,311 
Novo Nordisk (NVO) 636,848 
Johnson & Johnson (JNJ) 311,817 
Novartis (NVS) 172,943 
GlaxoSmithKline (GSK) 76,696 
Merck (MRK) 161,818 
Sanofi (SNY) 97,096 
 
Regarding total assets, Pfizer Inc. has a total value of $171,615 M, and comparing with similar companies of the industry the 
output after applying the criterion is the following (in green): 
 
Company Name Total Assets 
Brystol-Myers Squibb (BMY) 33,707 
Eli Lilly (LLY) 38,806 
Allergan (AGN) 128,986 
AstraZeneca (AZN) 62,256 
Novo Nordisk (NVO) 97,539 
Johnson & Johnson (JNJ) 141,208 
Novartis (NVS) 130,124 
GlaxoSmithKline (GSK) 59,081 
Merck (MRK) 95,377 
Sanofi (SNY) 104,672 
 
For Net Income, Pfizer Inc. registered a value of 7,215 and the performance of the peers is demonstrated below with the 
corresponding elimination criterion: 
 
Company Name Net Income 
Brystol-Myers Squibb (BMY) 4,457 
Eli Lilly (LLY) 2,738 
Allergan (AGN) 14,973 
AstraZeneca (AZN) 3,499 
Novo Nordisk (NVO) 37,925 
Johnson & Johnson (JNJ) 16,540 
Novartis (NVS) 6,712 
GlaxoSmithKline (GSK) 912 
Merck (MRK) 3,920 
Sanofi (SNY) 4,709 
 
The last elimination criterion used in order to select the four best comparable companies, was EBITDA. In terms of EBITDA 





Company Name EBITDA 
Brystol-Myers Squibb (BMY) 5,012 
Eli Lilly (LLY) 4,955 
Allergan (AGN) 7,210 
AstraZeneca (AZN) 7,475 
Novo Nordisk (NVO) 51,625 
Johnson & Johnson (JNJ) 24,890 
Novartis (NVS) 13,618 
GlaxoSmithKline (GSK) 4,425 
Merck (MRK) 10,820 










After all criteria applied to our peer group, the best four comparable companies are Johnson & Johnson, Novartis, Merck and 




Sales Market Cap. Total Assets Net Income EBITDA Peer 
 BMY NO NO NO YES NO NO 
LLY NO NO NO NO NO NO 
AGN NO NO YES NO NO NO 
AZN NO NO NO YES NO NO 
NVO NO NO YES NO NO NO 
JNJ YES NO YES NO YES YES 
NVS YES YES YES YES YES YES 
GSK NO NO NO NO NO NO 
MRK YES YES YES YES YES YES 
SNY YES NO YES YES YES YES 
 
Thenceforward, all computations about relative valuation were done using those four companies as a comparable (peers), and 
using the multiples Enterprise Value to EBITDA (EV/EBITDA), Enterprise Value to EBIT (EV/EBIT), Enterprise Value to Sales 
(EV/Sales), Price to Book Value (P/B), Price to Sales (Price/Sales) and Price to Earnings (P/E). 
 
Following table summarize all multiple results and the respective price target derived from those computations. 
 













































































2014 2015 2016 2017F 2018F 2019F 2020F 2021F Perpetuity
Net Debt 560 15,609 24,236 14,780 15,711 16,700 17,753 18,871 19,380
Short-term Debt 5,141 10,159 10,688 9,619 10,225 10,870 11,554 12,282 12,614
Long-term Debt 31,541 28,740 31,398 34,038 36,183 38,462 40,885 43,461 44,635
Total 36,682 38,899 42,086 43,658 46,408 49,332 52,440 55,744 57,249
Cash and Cash Equivalents 3,343 3,641 2,595 3,576 3,801 4,041 4,295 4,566 4,689
Short-term investments 32,779 19,649 15,255 25,302 26,896 28,591 30,392 32,307 33,179
Total 36,122 23,290 17,850 28,878 30,698 32,632 34,687 36,873 37,868
2014 2015 2016 2017F 2018F 2019F 2020F 2021F Perpetuity
Changes in Accounts Receivable 148 21 -134 16 17 19 20 21 22
Changes in Inventories 175 -199 365 119 127 135 143 152 156
Changes in Accounts Payable 297 254 871 518 551 585 622 661 679
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